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ABSTRACT
Glaucoma refers to a group of conditions characterized by death of RGCs,
increase in intraocular pressure is usually a precursor to glaucoma and irreversible optic
neuropathy leads to visual impairment and blindness. Recent advances have seen a surge
of new ideas and technologies to aid in the early detection, efficacious treatments and
neuroprotection. Despite advances we face several challenges in understanding the
pathophysiology of glaucoma. One of the many challenges scientists and
ophthalmologists are facing is, to better understand IOP, its role in glaucomatous damage
and design safer, more predictable IOP-lowering therapies. Another challenge is to find a
practical method or develop tools to understand the molecular pathways to study RGC
function and health to develop novel therapies for vision loss. This work leads to three
complementary insights on how to address these challenges. First, we used a novel
systems genetics approach to identify and validate genetic modifiers of IOP using the
enlarged BXD family of strains in combination with human GWAS glaucoma cohorts.
This will pave the way for improved drug development tailored to individual genotypes
for POAG. Second, we have combined systems genetics, bidirectional studies using
multiple species, meta-analyses, immunohistochemistry, FACS sorting and gene
knockdown studies to identify and validate the identity of a genetic modulator of Sncg, a
gene that has been previously implicated in RGC death in glaucoma. Outcomes of the
investigation may provide clues to understanding the molecular mechanisms that account
for the degenerative changes in RGCs in glaucoma. Third, we optimized a feasible,
reproducible, standardized flow cytometry-based protocol for the isolation and
enrichment of homogeneous RGC. This will allow for future careful assessment of
important cell specific pathways in RGC to provide mechanistic insights into the
declining of visual acuity in aged populations and those suffering from retinal
neurodegenerative diseases. Taken together these studies offer a concise outlook on use
of integrated systems science, molecular and imaging technologies as a needs-led
innovation in ophthalmology and visual health.
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CHAPTER 1.

INTRODUCTION

Primary Open Angle Glaucoma
Glaucoma is a group of disorders that have in common a distinct type of optic
nerve damage. The disease process is insidious such that central vision is usually not lost
until the disease is advanced and thus many cases are left undiagnosed and untreated (1).
For this reason, and others discussed below, glaucoma is a leading cause of blindness
worldwide. The most frequently diagnosed types are primary open-angle, angle-closure
and normal-tension, or low-tension, glaucoma.
Primary open angle glaucoma (POAG; OMIM 137760) is the most common form
of glaucoma. It is a progressive optic neuropathy with characteristic changes to the optic
nerve head and corresponding visual field defects (2, 3). Glaucoma affects 2% of
individuals of European descent (4)and up to 10% of individuals of sub-Saharan African
descent over 50 years of age (5, 6). The well-recognized risk factors associated with
POAG include older age, elevated intraocular pressure (IOP), ethnicity, family history of
POAG, myopia, and low diastolic perfusion pressure (7).
The main clinical features of POAG are an open iridocorneal angle and cupping
of the optic-nerve head (or optic disk), as well as optic disc hemorrhages and
parapapillary atrophy with corresponding loss of visual field (8, 9). From a
pathobiological point of view, POAG is characterized by progressive retinal ganglion cell
(RGC) death. RGC loss causes progressive deterioration of visual fields, leading to
peripheral loss of vision. It is well known that elevated IOP plays a major role in RGC
apoptosis and that reduction of elevated IOP often helps in slowing down the progression
of degenerative changes in glaucoma. However only one-third to half of all glaucoma
patients have elevated IOP at the initial stages (10-12). About 30-40% of patients with
glaucomatous visual field defects are being diagnosed as having normal tension
glaucoma (NTG) (13). Therefore, elevated IOP is now believed to be an important but
not the only factor responsible for optic nerve damage. Text after this run-in head starts
here and is styled Normal.
IOP as a major risk factor
IOP is a significant factor in the diagnosis and management of glaucoma. It is the
only known risk factor amenable to modification. It can be argued that elevated IOP is a
major risk factor and is also considered to be a causative factor in glaucoma (14). There
is a clear physiological association between high IOP and glaucoma. IOP can result from
ocular trauma, inflammation, dysgenesis or other forms of obstruction of the aqueous
humor drainage system in the trabecular meshwork of the iridocorneal angle by iris
tissue, pigment or other deposits. Clinically, IOP is closely associated with visual field
deterioration and optic nerve damage. It is estimated that the heritability for adult IOP
range from 0.29 to 0.62 (15, 16). Linkage studies have shown two regions to be robustly
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associated with IOP, one at 10q22 from a Tasmanian glaucoma pedigree, this region
contains BMPR1A, a bone morphogenic protein receptor—interesting because Bmp4 has
been implicated in increased IOP in mice (17). And another at 5q22 region which
indicates WDR36 gene which codes for WD Repeat Domain 36 in a West African cohort
(18, 19). A recent genome-wide association study (GWAS) for IOP also found associated
loci, one of which (TMCO1 gene—transmembrane and coiled-coil domains 1) overlaps
with a previously published POAG GWAS locus (20). Many large-scale multicenter
clinical trials, including the Ocular Hypertension Treatment Study, the Early Manifest
Glaucoma Trial, and the Advanced Glaucoma Intervention Study have shown that
reduction in IOP effectively delays or prevents glaucomatous visual damage (21, 22).
Therefore, lowering of IOP currently remains the only therapeutic option for mitigating
the visual deficits associated with POAG. All current treatments of primary open-angle
glaucoma are aimed at reducing IOP by medical or surgical means (23, 24).
Role of RGCs in POAG
The cell bodies of RGCs constitute the innermost layer of the retina; they are the
final output neurons of the retina. These neurons are fundamentally different from other
retinal neurons because they receive input from the photoreceptors via bipolar and
amacrine cells and have axons which exit the eye at the optic nerve head (ONH). The
optic nerve collects all the axons of the ganglion cells and this bundle of more than a
million fibers (in humans) then passes information to the brain.
In POAG, the RGC cell bodies and axons die, which leads to cupping of the optic
nerve head. The mechanism of RGC damage is complex. The damage can occur due to
many complementary mechanisms. Mitochondrial dysfunction has been proposed to play
a key role in RGC loss in glaucoma (Kong et al., 2009; Lee et al., 2010; Osborne, 2010)
it is the center stage for interactions between anti- and pro-apoptotic Bcl-2 family
members (25). Excitotoxic injury has been also proposed to be involved in RGC cell
death (26, 27). Most current hypothesis is that, excess glutamate binds to cell surface
ionotropic glutamate receptors, primarily N-Methyl-D-Aspartate (NMDA) receptors
(NMDAR), triggering massive Ca2+ influx and activation of pro-apoptotic signaling
cascades in neurons leading to cell death (28, 29). Other studies show that RGCs die by
apoptosis in models of acute optic nerve lesion (axotomy and crush) and experimental
models of glaucoma (30, 31). Intrensic apoptotic pathways such as JNK/c-jun and Bcl-2
gene family are known to play a major role in RGC cell death (32, 33). In addition,
oxidative damage occurs in experimental models of optic nerve injury and in human
glaucoma. For example, DNA damage as well as protein and lipid peroxidation products
accumulate in the TM and retina from experimental animals with ocular hypertension and
in POAG patients (34-36). The complement cascade is an important component of the
innate immune system to recognize and eliminate pathogens and foreign material. A
study showed that C1q, C3 or C4 undergo early upregulation in rat and primate glaucoma
models, DBA/2J mice, and human glaucoma (37-39). Interestingly, reactive glial cells
have emerged as mediators of RGC death in different injury modalities including ocular
hypertension. Glial cells exacerbate excitotoxic damage, produce pro-inflammatory and
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neurotoxic factors, and undergo detrimental changes that affects RGC viability. Although
there have been substantial advances in our knowledge towards cellular mechanisms of
how RGCs die in glaucoma, substantial hurdles remain to translate this knowledge to
clinical practice for neuroprotection (40).
Genetics of POAG
POAG is a genetically complex group of diseases, whose familial nature of
POAG has been recognized for decades. POAG is the main type of glaucoma in most
populations; and more than 20 genetic loci for POAG have been reported. About 5% of
(POAG) is currently attributed to single-gene or Mendelian-recessive traits (usually
early-onset forms of the disease), or may exhibit a heritable susceptibility consistent with
complex trait inheritance (typically adult-onset forms of the disease).
Our modern understanding of the genetic architecture of POAG has evolved since
the first gene for POAG, myocilin (MYOC), was mapped and identified. Since then,
more than 20 genetic loci for POAG have been reported (41). The best known and
studied loci are GLC1A on chromosome region 1q21-q24 spanning the MYOC gene (42),
the GLC1E locus (region 10p14-p15) with the Optineurin (OPTN) gene (43), and locus
GLC1G (region 5q22.1) containing the gene WDR36 (18). Other known genes with
significant association with POAG/IOP include; TMCO1 (20), antisense noncoding RNA
in the INK4 Locus (CDKN2B-AS1) (44), Growth Arrest-Specific 7 (GAS7) (20),
Caveolin 1(CAV1/CAV2) (45), and SIX Homeobox 6 (SIX1/SIX6) (44). However, only a
small number of patients with POAG have mutations in these genes. Currently, the
genetic origins of the majority of glaucoma cases are unknown, as the known genes
account for only a small fraction of heritable cases. The identification of genes (and their
protein products) that can cause or contribute to glaucoma will help define the underlying
pathophysiology as well as lead to the development of new DNA-based diagnostic tests
and novel therapeutic approaches.
Candidate gene studies
Family history is one of the risk factors of POAG, but the number of cases of
POAG caused by single gene mutation accounts for only a small portion of all POAG
cases. Numerous studies have focused on candidate gene approach based on either gene
expression or the function or structure of specific proteins in multiple glaucoma-related
tissues. This is simpler and cheaper than complete re-sequencing of candidate genes, and
has been proposed as a powerful means to identify the common genetic variants that
underlie complex diseases (46). The candidate gene approach has been successful for
several inherited ocular diseases. However, most glaucoma cases involve low-penetrance
risk alleles rather than mutations in known high-penetrant genes. This makes it difficult
to select the variants of target genes in a large number of genetic variants. Since the
fundamental pathophysiology of glaucoma is unknown, candidate gene studies will not
sufficiently explore the genetic basis of the disease. Usually there is inconsistency in the
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association and replication studies due to variations in the study design, diagnosis
method, sample size and ethnicity.
Genome-wide studies
GWAS approach has been performed in various common diseases and succeeded
in identifying new susceptibility genetic regions including POAG. GWAS are casecontrol studies, based on a comparison of unrelated but cases and control individuals
from a population using single nucleotide polymorphisms (SNPs) that segregate with the
disease or trait. A simple study design in GWAS includes four steps: (a) selection of a
large number of individuals with the disease or trait of interest and a suitable control
group; (b) DNA isolation, genotyping, and quality control; (c) statistical tests for
associations between the SNPs and the disease/trait; and (d) replication of identified
associations in independent population samples or experimental examination of
functional implications to verify a true association. This type of analysis is very efficient
and powerful in identifying causative genes, especially for complex diseases. GWAS
have greater power to detect the effects of common variants, since linkage disequilibrium
are measured in tens of thousands of bases (47).
Meguro et al. reported the first genome-wide significant (p = 2.5 × 10−9, odds ratio
(OR) = 2.80) association for SNP rs3213787 in SRBD1 in the Japanese NTG population
(48). Other POAG associated gene variants that GWAS identified include SNPs near
CAV1 and CAV2 in an Iceland cohort (45), the caveolin genes have been postulated to
influence transforming growth factor-beta (TGF-β) or nitric oxide signaling pathways
involved in POAG pathogenesis. The association of the TMCO1 locus with POAG has
been replicated in another GWAS for a Caucasian cohort (20). The ciliary body,
trabecular meshwork and retina show abundant TMCO1 expression. However, its precise
role in POAG pathogenesis is unclear. A recent study by Li et al. provided strong
evidence of an association at the CDKN2B-AS1 locus (rs2157719, OR = 0.71, p = 2.81 ×
10−33), and also identified SNP rs1192415 in the CDC7-TGFBR3gene (1p22) showing
significant association with POAG (OR = 1.13, p = 1.60 × 10−8) in the Asian, African and
European populations, as well as SNP rs4894796 in FNDC3B (3q25.31) showing a
significant association in Asians only (OR = 0.89, p = 7.93 × 10−8) (49). GWAS studies
by Wiggs et al. and Osman et al. in the Caucasian POAG and Japanese POAG cases,
respectively, have demonstrated a strong association of SNP rs10483727 located in the in
the intergenic region between the SIX1 and SIX6 locus (14q23) (50, 51). SIX6 has been
shown to express in the developing and adult human retina (52).
GWAS are advantageous since there is no need to include a specific disease
model, which can allow identification areas of previously unsuspected pathogenesis. The
pathogenesis of most cases of glaucoma, excluding those in which single gene defects
have been identified due to contributions from many different polymorphisms. So
likelihood of picking up an association depends on the ability to control for errors due to
bias and poor phenotyping. GWAS need large numbers of cases and controls to identify
the biological context in which statistically significant candidate variants act. This may
reflect linkage disequilibrium between the SNPs identified and the true causative
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functional variant. Therefore, fine mapping of the regions harboring the most significant
statistical signals is need to be followed up by GWAS. These type of studies have
significant cost implications.
Systems Genetics Approach to Study Glaucoma
Systems genetics is an approach to understand molecular architecture that
underlies complex traits. The multiple genetic and environmental factors that play a role
in glaucoma make it difficult to identify individual genes linked to this disorder. Still,
some genetic risk factors associated with forms of glaucoma have been identified in
genes that code for proteins involved in known biological pathways. Despite this
progress, determining which genes may be the most relevant to developing therapeutic
interventions for glaucoma has proven exceedingly difficult. The major obstacles being
that gene/disease associations reveal very little about the underlying basic molecular
biology and any implicated gene variant explains only a small proportion of an
individual’s overall risk for the disease. Recent advances in technology has provided
tools that are capable of tracking genome-wide expression changes occurring in
progressive pathological processes and diseases such glaucoma. It is becoming
increasingly evident that the application of network-based genetics or systems genetics
approaches can provide insights into not only the roles of individual genes or
developmental pathways but also illuminate relationships between different levels of a
biologic system, such as the genome, transcriptome, and phenome (53, 54).
Systems genetics is a relatively new branch of quantitative genetics that has the
goal of understanding networks of interactions across multiple levels that link DNA
variation to phenotype. Systems genetics involves an analysis of sets of causal
interactions among classic traits such as IOP, networks of gene variants, and
developmental/environmental/epigenetic factors. The main challenge is the need for
comparatively large sample size and the use of more advanced statistical and
computational methods and models. Genetic reference populations, which are genetically
well characterized lines, are often used in systems genetics studies as a source to study a
multitude of different phenotypes and to find the causal relations from networks of
genetic correlations.
Recombinant inbred strains
Recombinant inbred (RI) strains are a collection of genetic reference populations
commonly used in genetic mapping of Mendelian and quantitative traits. Bailey and
colleagues introduced the idea of using RI lines for detecting major-gene effects and to
establish linkage (55-57). Conventionally, RI strains are developed by crossing two
inbred parental strains. The inbred lines are mated repeatedly for 20 or more generations
to warrant they are at least 99% inbred (55). Consequently, each RI line produced has
two identical copies of each chromosome and is just a pure mosaic of the parental
genomes. These homozygous lines contain the allele of either one or the other parental
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strain. For a segregating trait, the linkage can be determined by matching the allelic
pattern for the locus across the RI strains to the previously known markers. This is known
as the strain distribution pattern (SDP). Generally, a qualitative trait is controlled by a
single major gene, in contrast complex quantitative traits are influenced by moderate
effects due to several genes. With the latest technologies, there has been a tremendous
improvement in genotyping of RI strains with new markers and increasing data on SDP.
RI strains are also used in identifying quantitative trait loci (QTLs) associated with
quantitative traits (58-60). This idea was first introduced in late 1970s by correlating
genetic marker information with quantitative phenotypes (61, 62). Classically, the
Pearson correlation was used to measure association and the strength of this association
was improved by using multiple markers and an interval mapping approach (63). The
effectiveness of the RI strains depends on the size of the panel; the big panels tend to map
the trait precisely. These strains are particularly useful for precise estimation of
phenotypes associated with low to medium heritability.
DBA/2J inbred strain as glaucoma mouse model
The development of new therapeutic drug targets for elevated IOP relies heavily
on animal models, which represent a valuable tool for understanding both the progression
and cause of glaucoma. The damage present at the time of diagnosis precludes the study
of disease development from onset. Additionally, obtaining retinas at different pathologic
states is difficult and is a limitation. Much of the progress in the study of glaucoma has
been driven by the development of rat models is due to similar ocular anatomy to
humans. They are readily available, easy to genetically manipulate and have a short life
span. All these reasons make rodents a very attractive models to use as research tools for
studying glaucoma. However, studies on mice have a distinct advantage over rats because
these animals enable us to conduct complex genetic manipulations in order to study the
function of crucial genes and pathways in glaucoma.
John et al developed DBA/2J as a mouse model of glaucoma that has become well
established over the past few years (64). DBA2J mice develop elevated IOP and severe
glaucoma like phenotype with age, followed by RGC death, and optic nerve
degeneration. The IOP elevation is subsequent to an iris disease that deposits pigment in
the ocular drainage structures. The iris transillumination defect is caused by mutations in
two different genes- Tyrp1 and Gpnmb. The first is the mutation in the b allele of tyrosine
related protein (Tyrp1b). Tyrp1 encodes a melanosomal protein that plays a role in
enzymatic and structural functions in these organelles. The second mutant gene is Gpnmb
which encodes a transmembrane glycoprotein found in multiple different cellular
structures. The Gpnmb gene carries a stop codon mutation (GpnmbR150X). These
mutations together lead to anterior chamber changes including pigment dispersion, iris
transillumination, iris atrophy, anterior synechia, and elevated IOP.
A significant advantage in using DBA2J mice include the inbred nature of these
mice, meaning that they have a fixed genetic background. Despite this, these mice exhibit
a high degree of variability and asymmetry in developing the disease (65).
Approximately 8-10% of the older DBA/2J mice have a combination of one normal, non-
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diseased retina and optic nerve, and one eye undergoing complete degeneration. Also, the
relevance of TYRP1 and GPNMB to human glaucoma is controversial since no exonic
mutations in either gene have been found in human glaucoma patients (66, 67). The
unusual interplay of the Tryp1 and Gpnmb genes in initiating the anterior chamber
disease is not related to POAG in humans.
BXD strains
The largest and best-characterized murine reference panel is the BXD family of
RI mouse lines (68) (Figure 1-1). The first of BXD lines from 1-42 were produce by
researchers at Jackson laboratory and lines 43-100 were produced at University of
Tennessee Health Science Center led by Dr. Robert Williams. The new set of BXD
strains from BXD 43-108 were produced from advanced intercrosses, which makes them
highly recombinant. These advanced intercross lines contain twice as many
recombinations as the older BXD strains. The complete genomic sequence data of both
the parents are publicly available (www.genenetwork.org).
The BXD strains are well suited for integrating data across multiple phenotype
domains spanning molecular, morphological, physiological, and behavioral traits. BXDs
have been used extensively in genetic and genomic studies of the eye and central visual
system (69-71). The DBA/2J strain of mice is one of the parental strains of the BXD
family. It closely mimics human hereditary pigmentary dispersion glaucoma. The greatest
utility of this BXD family is that it can be used to map the chromosomal positions of
sequence variants that cause differences in gene expression. Furthermore, reproducibility
of eQTLs in the BXD family and in an F2 cross between the same parental strains has
been reported to be very high (72).. Over the last two decades, the BXD family has been
exploited to study the genetics of immune function and infectious disease (73, 74). It has
also been used in behavioral and neuro-pharmacological research (75, 76). The eyes and
retinas of this BXD family have also been well studied for more than a decade, and we
now possess extensive cytological and morphometric data on their eyes and retinas that
can be studied with reference to differences in gene expression. Due to the fixed
genotypes of each BXD strain and the availability of massive databases of expression
data it is possible to study correlations between a phenotype and genotypes. We can also
study associations between two or more genes and identify upstream genetic regulators.
Genetic dissections of genomic data
QTL analysis
A forward genetics approach that is frequently used for studying complex traits in
animal models is called QTL mapping. QTL analysis is a statistical method used to
measure a particular quantitative trait across a genetically diverse population and
screening for associations between genotypic and phenotypic variation (77, 78). The
main purpose is to detect the polymorphisms underlying the phenotype of interest by
scanning for alleles that co-vary with the traits. The regions of the genome that show a
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Figure 1-1.

BXD breeding scheme

All BXD lines were derived by crossing C57BL/6J and DBA/2J parents. The resulting
heterozygous F1 individuals were again crossed to generate genetically diverse but nonreproducible F2 animals. These F2 progeny were iteratively inbred until generation F20+,
at which point each line represents a unique mosaic of B6 and D2 alleles.
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significant association with a phenotype are considered QTL. In short, the mapped QTL
is the implicated region harboring a single gene that affects an associated phenotype.
However, it is possible that a QTL may harbor or be controlled by multiple genes, noncoding RNA (ncRNA) species, epigenetic mechanisms, or in combinations. Markers like
SNPs and microsatellites are used for genotypic distinctions (79). Many QTL mapping
studies have been carried out in human populations, but due to the excessive non-genetic
variance contributed by each subject’s unique environment and life experiences, it
presents a tremendous amount of noise (80). In contrast, mice are a highly attractive
model for the purpose of dissecting complex traits. Mice are small in size, they have
relatively low maintenance costs and short gestation period. With increasing
advancement in technology there is an ever-expanding arsenal of genetic tools. QTL
mapping studies are primarily conducted using inbred strains of mice and their various
inbred lines (81).
The following are the four steps to achieve QTL mapping; the first step is to
measure variation in a quantitative trait in a genetic reference population such as inbred
mouse strains. The prerequisite is to have the quantitative traits that show phenotypic
variability among the inbred strains. The phenotypic variation (VP) is due to the genetic
(VG), environmental factors (VE) and interactions between them. The higher the variation
due to genetic factors, the better is the mapping resolution of QTLs. The second step is to
determine the heritability of the observed phenotypic variation. Heritability (H2) you an
estimation of the genetic contribution to variation in phenotypic trait. It is calculated as
the ratio of phenotypic variance that is due to genetic factors to the total variance
(Equation 1.1).
H2 = VG/VP where VP = VG + VE

(Eq. 1.1)

The third step is to proficiently collect the phenotype and genotype data from the inbred
strains. The phenotype is any measurable or quantitative trait and genotype are various
markers such as SNPs or copy number variants (CNVs). Such genotype markers are
unique for individual strains and follow a particular strain distribution pattern. The fourth
step is to generate a linkage map and perform the statistics generating a QTL. The most
commonly used methods for doing a linkage analysis are- regression method, likelihood
method, variance component method and the Bayesian method. For our study, we use
GeneNetwork (http://www.genenetwork.org/webqtl/main.py) , which utilizes interval
mapping to estimate the position of QTLs across a chromosome (60, 71, 76, 82). The
significant linkage between the phenotypic trait and genotype is generated by using
permutation test and by calculation of the likelihood ratio statistic (LRS).
Expression QTL
Technological advancement has enabled us to use systems-level approach in
identifying disease-associated genes using gene mapping methods and high throughput
molecular data. QTL mapping methods were previously used for classical physiological
or behavioral phenotypes, but now we can identify QTLs for genetic factors influencing
high-throughput measures of transcript, protein and metabolite. This approach of
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mapping effects of genetic variation on gene expression has been utilized in numerous
studies in humans (83-85), mice (82, 86)and other organisms. Collectively, the regions of
genome (loci) in which gene expression level is influenced by specific genetic variation
are termed expression quantitative trait loci (eQTL). eQTL analysis provides an
understanding of how changes in the genome affect transcript expression levels,
providing further insight into how transcripts regulate disease. Typically, in eQTL
mapping, regulatory variants have been commonly divided into cis or trans acting QTLs
depending on their location and mechanism by which they affect gene expression. In the
classical definition, cis-eQTLs refers to genetic variants that affect expression of a locus
on the same DNA molecule, thus in allele-specific fashion. In contrast trans-eQTLs are
expected to affect gene expression in an allele independent manner. Much of the variation
at the genomic level that affects a trait occurs by cis-acting sequence differences. TranseQTLs usually have smaller effect sizes and seem to be more tissue-specific than ciseQTLs (86, 87), thus complicating their detection.
Application of Flow Cytometry in Eye
Flow cytometry is an analytical method that measures optical and fluorescence
characteristics of single cells (or any other particle, including nuclei, microorganisms,
chromosome preparations, and latex beads). Flow cytometry is rapid, reproducible, and
sensitive, and can be applied to living cells in suspension, making it especially an
attractive method in the study of cytological specimens. The ability to simultaneously
measure multiple parameters on a cell-by-cell basis is perhaps the most powerful aspect
of analytical flow cytometry. Characteristics that can be measured include cell size,
cytoplasmic complexity, DNA or RNA content, and a wide range of membrane-bound
and intracellular proteins. Cellular and physical properties, such as size or surface area
(represented by forward angle light scatter) and internal complexity/granularity
(represented by right-angle scatter) can resolve certain cell populations. The methodology
relies on the use of antibodies conjugated to different fluorochromes, each with similar
excitation wavelengths and different emission wavelengths (or “colors”). This allows
several cellular properties to be measured simultaneously based on the mechanism of
action of the fluorochromes associated with a dye, the specificity and sensitivity(88).
Certain dyes such as fluorescein isothiocyanate [FITC], propidium iodide [PI], bind to
specific proteins/lipids/nucleic acids to increase fluorescence. The fluorescence intensity
may vary based on cellular physiological parameters such as pH, membrane potential, as
well as enzymatic activity (fluorogenic substrates) such as esterases, peroxidases, and
peptidases.
Instrumentation
Flow cytometers comprise three main systems: fluidics, optics and electronics.
Inside a flow cytometer, cells in suspension are drawn into a stream created by a
surrounding sheath of isotonic fluid that creates laminar flow, allowing the cells to pass
individually through a sensing point which is called the hydrofocus point. At the sensing

10

point, a beam of monochromatic light, usually from a laser, intersects the cells and
produces the fluorescence emission. Emitted light is scattered in different directions and
is collected via optics that directs the light to a series of filters and dichroic mirrors that
isolates particular wavelength bands. The light signals are detected by photomultiplier
tubes and converted into electrical signals by the optical and electronics system. The
electric signals are converted into numeric data by different algorithms contained in the
data acquisition component. Resulting data is analyzed using as additional software and
represented in either single or two dimensional plots.
Flow cytometry application in ocular diseases and retinal cell biology
A growing body of literature supports the application of flow cytometry in many
fields of research such as immunology, cancer, cell biology, stem cell and biomolecular
screening (89-91). Its application is not limited to just basic research where they are used
for performing tasks that require analytical precision and high throughput. Flow
cytometry instrumentation plays a key role in hospital and medical centers, where they
are widely used for clinical diagnosis. However, in spite of the breadth of applications
straddling many fields, the use of flow cytometry in neuroscience has been largely
unexploited; being perceived as challenging and has seen only a steady increase in
interest until recent years. Over the last decade, flow cytometry has proved useful in
studying neuronal population in brain, CNS and eye (92, 93). Increased awareness of the
quantitative and overall analytic potential of flow cytometry has recently encouraged its
more widespread use in ophthalmology.
The analysis of retinal cells by flow cytometry in basic and clinical vision
research is becoming more common in recent years. Cousins et al. identified and
analyzed antigen-activated lymphocytes and their role of infiltrating immune effectors in
ocular inflammatory disease using flow cytometry. They distinguished activated T and B
lymphocytes from mouse eyes (94). Flow cytometry was also used later by Davis et al. to
diagnose intraocular lymphoma and ocular inflammatory disease using patient vitreous
specimens (95). Researchers have also utilized this technique to investigate HLA-DR on
conjunctival epithelial cells from patients with cystic fibrosis using monoclonal
antibodies to HLA-DR (96). Another example is in dry eye disease where Chen et al.
used this analytical method to delineate the CD4+T-cell populations in normal, acute
DED, and chronic DED mice (97). Flow cytometry of vitreous fluid samples has proven
useful in the diagnosis of intraocular lymphoma, a subset of primary CNS lymphoma
(98). A retrospective study of 20 patients with suspected intraocular lymphoma on slit
lamp examination, 7 of 10 patients diagnosed with intraocular lymphoma by vitrectomy
had positive flow cytometry findings (99). Flow cytometry had higher positive and
negative predictive values compared with cytology. Several other retinoblastoma studies
have looked at cell cycle regulation, proliferation and apoptosis using flow cytometry.
(100-102)
Many laboratories have used standard intracellular or surface markers to identify
neuronal cell types in the retina. In 2011, Samuel et al. used antibodies against recoverin
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to detect photoreceptors, syntaxin for amacrine, Chx10 for bipolar, PKC for rod bipolars,
Thy1 for RGCs (103). They were able to identify changes the surface marker levels in
these cell types due to age related changes. A similar study by Portillo et al. identified
microglia/macrophages, endothelial cells, astrocytes, photoreceptors, ganglion neurons
and Müller cells using CD11b, CD31, glial fibrillary acidic protein, rhodopsin, Thy1 and
vimentin, respectively in mouse retinas (104). Apart from identifying subtypes of cells,
one can also assess viability and damage in neuronal cells. Chang et al., measured
viability and damage using BrdU, in small, medium and large RGCs in rats after eye
injury by N-methyl-D- aspartic acid (NMDA)-injury. They identified the RGCs using
Fluoro-Gold (FG) and were able to determine the size of the RGCs using flow cytometry.
The damage was assessed using FG vs Thy1 intensity (105). The most common
application of flow cytometry is assessment of toxicity, apoptosis and oxidative stress.
Another utility of FACS is the ability to quantify specific neuronal populations.
Few successful attempts have been made in past, Kennedy et al. performed a simple
technique to quantify rod outer segment phagocytosis in cultured RPE cells using FITC
labeled rod outer segment to tag rod photoreceptors (106). Srinivastava et al. analyzed the
RPE cell line ARPE19, human skin fibroblasts and human corneal epithelial cells by
determining RPE65 protein expression and epithelial and fibroblast proteins (107). By
focusing on identification of novel surface markers we can isolate subpopulations of
retinal cells using Fluorescence-activated cell sorting (FACS). FACS of live cells
separates a population of cells into sub-populations based on fluorescent labeling. Using
FACS, Xu et al., isolated CD133+CD44+ retinal cells to study cell type composition of
retinoblastoma tumors in mouse (108). Similarly, Feodorova et al., used size based
inclusion method to isolate rod perikarya from adult mice, based on their high backscatter
of heterochromatin in their nucleus (109). Lakowaski et al., used combination of five cell
surface markers to facilitate the isolation of photoreceptor precursors, with a phenotype
CD73(+)CD24(+)CD133(+)CD47(+)CD15(−) from three-dimensional model of retinal
differentiation from mouse embryonic stem cells (110). Apart from these, flow cytometry
and FACS can be utilized in many other domains and new applications have been
developed in ophthalmology, for investigating ocular surface biology and
pathophysiology.
Flow cytometry has also proved useful in studying glaucoma-associated changes
in the eyes. Liu et al. have used flow cytometric study to assess the amount of
inflammatory cells or cellular debris induced by lase iridotomy, which is a treatment
method for pupillary-block glaucoma (111). A similar study by Cvenkel et al.,
determined the levels of IL-8, IL-1B, IL-6, IL-10 in aqueous humor of patients who
underwent antiglacomatous surgery by flow cytometry (112). One of the implications of
pathological changes associated with glaucoma is oxidative stress which leads to
mitochondrial dysfunction. McElnea et al. examined those changes in human lamina
cirbrosa cells from glaucoma donors. They evaluated mitochondrial membrane potential
(MMP) and intracellular calcium [Ca2+] levels by flow cytometry using the JC-1
(5,5′,6,6′-tetrachloro-1,1′,3,3′-tetrabenzimidazolecarbocyanine iodide) and fluo-4/fura red
probes respectively (113). John and colleagues utilized flow cytometry to demonstrate the
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natural deficiency of CD94 that underlies the DBA/2J mice, concluding it is not a
pathogenic factor for glaucoma progression (114).
Research Aims
Aim 1: To identify the candidate gene that modulates IOP in mouse and test
translational validity of the mouse candidates using the cohorts of human glaucoma
patients
1. Which gene variants modulate IOP in BXD mice strains?
2. Do mouse candidate genes translate to human glaucoma patients?
Aim 2: To identify and validate regulator of Sncg in primary mouse RGCs
1. Can we use systems genetics to identify upstream modulator of Sncg?
2. Can we combine systems genetics with other molecular techniques to validate the
candidate gene?
Aim 3: To isolate and validate primary murine RGCs from healthy and
recombinant inbred mouse model of elevated IOP
1. Can we isolate primary murine RGCs using flow cytometry?
2. Can we apply this protocol to isolate RGCs from mouse model of glaucoma?

13

CHAPTER 2.

SYSTEMS GENETICS APPROACH TOWARDS UNCOVERING
THE GENE MODULATORS OF IOP
Introduction

Our aim was to identify new candidate gene variants for high IOP and to apply
systems genetics approach to identify networks of genes that are critical for IOP. In this
study we have systematically measured IOP across a large subset of BXD strains at 9.113 months of age. These quantitative measurements have been deposited to an openaccess web service for systems genetics (www.genenetwork.org). We identified
candidate gene variants by stringent stepwise refinement based on eQTL mapping,
correlation analyses (direct and partial Pearson test) and single nucleotide polymorphisms
(SNPs). We combined mouse SNPs with human GWAS glaucoma cohorts from
GLAUGEN/NEIGHBOR consortium database in an effort to identify and validate any
causal SNP within candidate genes. Here, we report for the first time a systems-genetics
analysis of the genetic components regulating IOP (Figure 2-1).
Methods
BXD strains
IOP study: A total of 545 mice were used in this study Age 9.1-13 months (548
mice from 66 BXD strains) Appendix A, Table A-1. The gender distribution was
relatively equal with 313 females and 235 males being included. All procedures
involving mice were approved by the Animal Care and Use review board of UTHSC and
followed the Association of Research in Vision and Ophthalmology (ARVO) Statement
for the Use of Animals in Ophthalmic and Vision Research in addition to the guidelines
for laboratory animal experiments (Institute of Laboratory Animal Resources, Public
Health Service Policy on Humane Care and Use of Laboratory Animals). Animals were
housed under cyclic light (12 hour on: 12 hour off) with 35% humidity in a specificpathogen free (SPF) facility at UTHSC. Animals were fed a 5% fat Agway Prolab 3000
rat and mouse chow (Breeder Chow, Teklad) and water ad libitum.
IOP measurement
IOP was measured using the induction–impact tonometer (Tonolab tonometer,
Colonial Medical Supply, Franconia, NH) for rodents according to the manufacturer’s
recommended procedures. For measuring the IOP, the tonometer was fixed in a vertical
position to a support stand by means of clamps. The mouse was gently restrained by hand
on an adjustable stand, and the eye was oriented in such a way as a distance of 1–4 mm
was maintained between from the tip the probe to the cornea of the eye. Six consecutive
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Figure 2-1.

Illustrated summary

A systems genetics based study to identify and validate genetic modifiers of IOP using
the enlarged BXD family of strains in combination with human GWAS glaucoma
cohorts. In future, this will pave the way for improved drug development tailored to
individual genotypes for POAG.
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IOP readings were averaged. IOP readings obtained with Tonolab have been shown to be
accurate and reproducible in different mouse strains, including DBA/2J (115).
Identification of significant genes for IOP in mouse and human
IOP data generated from 9.1-13 months old BXD strains was integrated into the
GeneNetwork database. The identification and mapping of phenotypic QTL (pQTL) was
performed by linking trait data to genotypes at known genetic marker loci using the
WebQTL module on GeneNetwork (http://www.genenetwork.org/). Genome wide
significance levels were estimated by performing 2000 permutations based on our
published methods (Lu et al., 2011a; Lu et al., 2011b; Swaminathan et al., 2013). This
analyses produces a LRS score, providing us with a quantitative measure of confidence of
linkage between the IOP and SNP markers. For the identification of single QTLs, interval
mapping analyses were performed across all chromosomes. The parental strains were
included in all mapping analysis. Composite interval mapping was performed for IOP at
9.1-13 months, choosing genetic markers with highest LRS at the single QTL region or
interacting loci from pairwise interaction scans, by factoring out of the effect of the preeminent QTL the power to identify secondary QTLs on other chromosomes increased.
Human Genome-wide genotype data were obtained from the NEI Glaucoma
Human Genetics Collaboration (NEIGHBOR) and the Glaucoma Genes and Environment
(GLAUGEN) consortia, containing whole genome genotypes for 2170 cases and 2347
controls. 495,132 SNPs were analyzed for GLAUGEN and 523,528 SNPs for
NEIGHBOR (116). Logistic regression to assess the association between individual SNPs
and POAG was done using PLINK v1.07. The human GWAS significance values were
Bonferroni corrected for multiple comparisons using the total number of homologous
genes compared and the number of tests used.
eQTL analysis of IOP candidate genes
In this study, we aimed to infer causal mechanisms for IOP variation in BXD.
Observing difference in gene expression that result from variants in the identified
genomic region increases the confidence that this locus harbors causal candidates
underlying the IOP peaks. Therefore, we chose to restrict our candidate search to the
genes located in significant eQTL region for IOP. Candidate gene was identified using
the GeneNetwork/UCSC Genome browser. Gene expression can be used as a micro trait
to map regulatory eQTLs for the differences in mRNA expression levels over the panel of
BXD lines since it’s a heritable trait. Whole eye expression levels were used as
quantitative traits and implemented into interval mapping analyses to identify regulatory
loci. The HEI Mouse Eye Dataset contains the data analysis of 221 Affymetrix M430 2.0
arrays (Affymetrix, Santa Clara, CA). This database presents the whole eye transcriptome
profiles of 80 strains of BXD mice aged between 2 and 4 months (117). Whole eye
database was used since IOP modulation is facilitated by tissues in anterior chamber of
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the eye. eQTL for a specific transcript was denoted cis-QTL if the associated marker was
localized within a 10 Mb distance of the gene position.
Immunohistochemistry
Mouse and human donor whole eye sections (10 μm) were blocked with 10%
normal goat serum in PBS containing 0.25% triton X-100 for 30 min at room
temperature, then incubated overnight at 4°C with the anti-CACNA2D1 primary antibody
(Bioss Antibodies, Woburn, MA) diluted in the same buffer. After three washes with
PBS, slides were incubated at room temperature for 2 hours with Alexa-Fluor-488conjugated secondary antibody (Invitrogen, Waltham, MA) and TO-PRO-III iodide
(1:4000; Invitrogen) as a nuclear counterstain, washed with PBS again, and mounted with
Vectashield anti-fade mounting medium (Vector Laboratories, Burlingame, CA).
Sections were viewed and images were obtained using a Nikon C1 confocal microscope
(Nikon, NY) within the Imaging Core Facility in the Hamilton Eye Institute. EZ-C1 free
viewer software was used for image acquisition and processing.
Statistics
To determine how much of the variation in candidate gene across the cohort was
due to genetic effects, we calculated the heritability of the candidate gene using the
formula of Hegmann and Possidente based on our published methods. Pearson productmoment correlations were calculated using the Correlation matrix tool available in
GeneNetwork. Pearson correlation measures the strength of a linear association between
two variables and is denoted by r, which in our case is IOP (mmHg) and Cacna2d1
mRNA expression. Within-strain and between-strain variances were calculated with
analysis of variance (ANOVA) using SAS 6.0.
Results
Study design for genetics of IOP
We measured IOP in 66 strains of BXD including both males and females
Appendix A-1, Table A-1. IOP was measured at 9.1-13 months of age. One of the
advantages of measuring IOP at 9.1-13 months of age is that at this stage of life span
these mice strains have already developed high IOP and the process of optic nerve
damage has started. The main advantage of the genetically diverse BXD over non-inbred
strains (such as an F2 intercross) is that the heritability of a trait can be accurately
measured and reproduced since the strains lack heterozygosity (Figure 1-1). The
differences among the isogenic strains is essentially due to genetic effects whereas
differences within the strains is due to environmental effect (118). BXD strains serve as a
tool for mouse genetics due to the conservation of the mammalian physiology.
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BXD family has a wide variation in IOP
Since glaucoma is a complex disease caused by the combined effect of genetic
and environmental risk factors we improved the power and precision of QTL mapping
studies by including large number of strains (i.e genotypes) in the genetic study of IOP
using BXDs. Among strains IOP varied (Figure 2-2) with BXD38 having the lowest IOP
of 9.60.92 (mmHg SEM) and BXD44 having the highest at 21.821.67. The average
IOP among all BXDs was 15.670.29. The parental lines, C57BL/6J and DBA/2J, had
IOP levels of 15.220.77and 16.84 0.70, respectively (Figure 2-2). Heritability was
calculated as the ratio of the within-strain variance to total sample variance. Based on our
previous published study (119), heritability (h2) for IOP for BXDs at 9.1-13 months
averaged to ~0.31. This value implies that 31% of the total trait variance is attributable to
genetic factors and is comparable to that of other ocular traits to which QTL mapping has
been applied successfully. The more heritable a trait, the higher the likelihood it will map
to significant QTLs. Consistent with this significant heritability value, IOP becomes a
particularly attractive trait for genetic dissection. Interestingly, Tyrp1 and Gpnmb
genotypes did not influence IOP in BXD strains at 9.1-13 months (Figure 2-3A). There
was no statistically significant correlation between the IOP and those genotypes (Figure
2-3B). IOP in BXD strains at 9.1-13 months has no statistically significant sex
differences and no strong correlation between males and females. They fall within 95%
confidence interval (Figure 2-4). This indicates that IOP could be a phenotype where
variation cannot be reliably attributed to genetic factors (i.e., variation is due to
environmental or technical influence).
QTL on Chr5 link causal loci for IOP
We mapped the variation in IOP to a narrow locus at the distal tip of Chr 5,
peaking at or beyond reference SNP rs13478120 (LRS=19.6, LOD=4.25, Figure 2-5),
which corresponds to human Chr 7:81,946,444 bp to 82,443,798 bp. IOP does not map to
either Tyrp1 or Gpnmb locus (Figure 2-6). Therefore, polymorphisms within this QTL
must be modulating IOP at 9.1-13 months of age.
Initial identification of candidate gene in the Chr 5 QTL region
To determine the candidate gene variants that modulate IOP we used the
following criteria:
1.
2.
3.
4.
5.
6.

Pearson correlation analysis
partial correlation analysis
location within confidence intervals of murine QTLs
expression in the eye
gene size
true cis modulation of candidate genes in eye and/or presence of coding
differences segregating among progeny
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Figure 2-2.

IOP levels across BXD strains and parental strains

Rank-ordered IOP levels across the BXD recombinant inbred family. BXD strains and parental strains are represented in grey and
black bars, respectively. Values denote IOP levels on mmHg scale (meanSEM).
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Figure 2-3.

Tyrp1 and Gpnmb genotypes do not influence IOP

(A) BXD strains carrying wild type alleles of both Tyrp1 and Gpnmb (WT/WT; Blue
bar), mutant of Tyrp1 and wild type allele of Gpnmb (MUT/WT; green bar)., wild type of
Tyrp1 and mutant allele of Gpnmb (WT/MUT; yellow bar), mutant alleles of both genes
(MUT/MUT; red bar). (B) The plot shows average IOP versus genotypes with or without
Tyrp1 and Gpnmb mutations in BXD strains at 9.1-13 months (n = 66).
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Figure 2-4.

Correlation of IOP for females and males at 9.1-13 months

IOP in BXD strains at 9.1-13 months has no statistically significant sex differences and
no strong correlation between males and females.
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Figure 2-5.

QTL mapping for IOP

A significant QTL for IOP is present on chromosome 5. Red and gray horizontal lines dictate significant and suggestive thresholds,
respectively.

22

Figure 2-6.

QTL mapping for Tyrp1 and Gpnmb in BXD strains eyes

A significant QTL for Tyrp1 is present on chromosome 6. A significant QTL for Gpnmb is present on chromosome 4. Yellow bar
represents the frequency of the peak QTL. Red and gray horizontal lines dictate significant and suggestive thresholds, respectively.
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7. plausible biological link to IOP and glaucoma
8. presence of SNPs in the GLAUGEN and NEIGHBOR human GWAS studies of
POAG and IOP
To identify the gene candidate, we first performed Pearson correlation by
generating a list of top 500 correlates of IOP within the whole eye database based on our
published methods (82). Out of top 500 gene correlates, Cacna2d1 (Pearson correlation
value: r=0.440; p=0.0003) and Sema3e (Pearson correlation value: r=0.295; p=0.02) were
the only two genes located in the QTL peak at Chr5 (Figure 2-7). To identify the best
candidate, we performed partial correlation analysis (120) (Figure 2-8). By controlling
for the genetic variability associated with QTL peak at Chr5, we were able to identify a
single candidate, CACNA2D1 (partial Pearson correlation value: r2=0.331; p=0.0093).
CACNA2D1 is known as Calcium Channel, Voltage-Dependent, Alpha 2/Delta Subunit 1
(Figure 2-9). The gene encodes for a preproprotein which is cleaved into multiple chains
that comprise the alpha-2 and delta subunits of the voltage-dependent calcium channel
complex. Calcium channels mediate the influx of calcium ions into the cell upon
membrane polarization (121). Mutations in this gene can cause cardiac deficiencies,
including Brugada syndrome and short QT syndrome (122) (Figure 2-10).
Genetic polymorphisms underlying variation in Cacna2d1 contribute to changes in
IOP
The expression of Cacna2d1 transcript in the whole eye among BXD strains
varied (Figure 2-11) with BXD71 having the lowest Cacna2d1 gene expression of
6.910.24 (expression Log2  SEM) and BXD48a having the highest at 9.710.33. The
average expression among all BXDs was 8.350.37. The parental lines, C57BL/6J and
DBA/2J, had Cacna2d1 expression levels of 9.5 0.07and 7.54 0.15, respectively
(Appendix A, Table A-2). The simple interval map shows a significant cis-eQTL for
Cacna2d1 on proximal Chr5:14.324112 with in the 5Mb of gene location (Figure 2-12).
The maximum LRS score of the locus was 143, which is equivalent to a LOD ratio of
31.01. Cacna2d1 gene has a 69% variance, which is explained by the single peak QTL at
Chr5. The majority of BXD strains with the D parental allele have low expression of
Cacna2d1 in the eye, while those with the B parental allele have higher expression of the
gene (Figure 2-13). Cacna2d1 is highly polymorphic in both mice and humans. We
identified known genetic variability between C57BL/6J and DBA/2J strains in Cacna2d1
gene and its flanking region within the eye using UCSC genome bioinformatics site
(http://genome.ucse.edu) (Figure 2-14). We identified five synonymous coding SNPs
within Cacna2d1 gene, 866 non-coding SNPs and 177 insertions/deletions, making this
gene highly polymorphic (Table 2-1). These polymorphisms segregate among the BXD
strains. Similarly, in humans, CACNA2D1 has 8801 exonic SNPs, 44 of which are nonsynonymous. There are also 7 CNVs and 5 InDels segregating in humans
[http://www.genecards.org/cgibin/carddisp.pl?gene=CACNA2D1] (Table 2-2).
The next step in our analysis was to obtain SNP level p-values for association
with GLAUGEN and NEIGHBOR human GWAS studies of POAG and IOP (116).
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Figure 2-7.

The screen shot depicts the Pearson correlation analysis using the tools available on GeneNetwork

Pearson correlation analysis listed two genes- Cacna2d1 and Sema3e within the QTL peak. The genes highlighted in yellow depicts
top candidate genes for IOP modulation at 9.1-13 months of age based on Pearson correlation analysis.
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Figure 2-8.

The screen shot depicts the partial correlation analysis using the tools available on GeneNetwork

Partial correlation analysis listed only Cacna2d1 within the QTL peak. The genes highlighted in yellow depicts top candidate gene for
IOP modulation at 9.1-13 months of age based on partial correlation analysis.
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Figure 2-9.

Zoomed-in view of QTL map for IOP

A significant QTL for IOP is present on chromosome 5 between 14-19Mb. Cacna2d1 is
the candidate gene located in the peak QTL. Black vertical line shows the location of the
candidate gene. Red and gray horizontal lines dictate significant and suggestive
thresholds, respectively.
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Figure 2-10. Subunit structure of L type calcium channel with description.
α1, β and  subunits are in blue. α2 and subunits are in red with a disulphide bond
between them. α21is GPI anchored to the plasma membrane.
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Figure 2-11. mRNA rxpression levels of Cacna2d1 across BXD strains and parental strains.
Rank-ordered mean Cacna2d1 mRNA expression levels across the BXD recombinant inbred family. Values denote normalized
relative expression levels on Log2 scale (meanSEM).
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Figure 2-12. A significant cis-eQTL for Cacna2d1 is present on chromosome 5 at 14-19 Mb.
Red and gray horizontal lines dictate significant and suggestive thresholds, respectively. The purple triangle indicates the location of
Cacna2d1 within the mouse genome.
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Figure 2-13. Cacna2d1 expression in whole eye of BXD strains attributable to the
genotype
Correlation between the trait values (here, Cacna2d1 expression levels) and the genotype
at the peak location. The majority of BXD strains with the D parental allele have low
expression of Cacna2d1 in the eye, while those with the B parental allele have higher
expression of the gene.
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Figure 2-14. UCSC Genome Browser illustration of the gene structure and location of SNPs associated with Cacna2d1 gene
Graphic depiction of Cacna2d1 gene with SNPs on chromosome 5 of the mouse genome. Reference Sequence mRNAs are
represented in blue and known mRNAs are represented in black.
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Table 2-1.

Summary of candidate gene Cacna2d1 in mouse

Candidate
Gene

Probe Set I.D

Gene
Location

Cacna2d1

1446324_at

Chr5: 15,440,50915,880,329 bp

Table 2-2.

Mean
Expression
Level
8.5

Max LRS and
Location

Cis eQTL
(Yes or No)

SNPs and
Indels

P-Value

143

Yes

 Non-coding
SNPs: 866
 Synonymous
SNPs: 5
 InDels: 177

2.43x10-5

Summary of candidate gene Cacna2d1 in humans
Candidate
Gene

Location

SNPs and Indels

SNP
I.D

P-Value

CACNA2D1

Chr 7:
81,946,44482,443,798
bp

 Coding SNPs: 398
 Non-coding SNPs:
17,940
 InDels: 45

rs4732474

0.0075
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Association analyses were carried out using the SNP genotypes of the CACNA2D1 gene
and flanking regions. The results showed evidence of weak associations between
rs1022418 (p=0.03; Odds ratio=1.17) of the CACNA2D1 and normal tension glaucoma
subset as well as rs6467882 (p=0.04; Odds ratio=0.87) of the CACNA2D1 and high
tension glaucoma subset. Furthermore, based on the inputted genotypes, rs4732474 of
CACNA2D1 showed a genome wide nominal association with the combined normal
tension and high tension glaucoma populations (i.e POAG). The p-value of rs4732474
was 0.0075 and odds ratio was 1.14, which is significant at gene level. None of the SNPs
remained genome wide significant after correction for multiple testing even when linkage
disequilibrium structure of the SNPs was taken into account, however rs4732474 was
significant at gene level since the p-value was less than 0.05.
CACNA2D1 is localized in the mouse and human eye
To compile additional evidence to support our hypothesis, we performed
immunohistochemistry (IHC) to determine the localization pattern of CACNA2D1 in
mouse and healthy human donor eyes. In mouse retina, CACNA2D1 is prominently
localized in the trabecular meshwork, ciliary body and ciliary muscle (Figure 2-15).
CACNA2D1 immunoreactivity was also observed in the nerve fiber layer, inner
plexiform layer and outer nuclear layer was also occasionally observed (Figure 2-15).
Positive staining and localization of CACNA2D1 in the mouse eye was further
corroborated by immunofluorescence microscopy analysis in human donor eyes (Figure
2-16).
Discussion
POAG is often regarded as ‘thief of sight’ and IOP is a highly heritable risk factor
POAG, this makes is the only target for current glaucoma therapy (14). But the genetic
factors which determine IOP are largely unknown. In this investigation, we have
combined cutting edge methodologies of systems genetics, bidirectional studies using
multiple species, meta-analyses and immunohistochemistry studies to identify a novel
genetic modulator of IOP. We systematically explored sources of genetic variation in the
IOP. We identified a novel QTL for IOP on chromosome 5. By combining our QTL
analyses with expression correlation analyses, human GWAS and literature review, we
identified a cis-regulated geneCacna2d1 that may enable a deeper understanding of
IOP and glaucoma.
POAG has an insidious onset and low natural course hindering a definite
diagnosis at an early stage. Diagnosis is usually non-uniform due to etiological and
clinical heterogeneity of POAG. Due to this, the current gene-finding in POAG focuses
on the adult-onset POAGs where relatively few people would be available to participate
thus limiting the identification of large affected families for gene mapping by linkage
analysis (123). These limitations fuel the need for the use of a genetic reference
population of RI strains, from which diverse phenotypes and genotypes can be collected
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Figure 2-15. Cellular localization of CACNA2D1 in C57BL/6J mouse eye
Sections from C57BL/6J mouse anterior chamber angle and retina were labeled with
antibodies against CACNA2D1. TO-PRO-III iodide staining labeled nuclei of all retinal
cells (blue). Abbreviations: TM=trabecular meshwork; CB=ciliary body; CM=ciliary
muscle; SC= schlemm's canal; GCL=ganglion cell layer; INL=inner nuclear layer;
ONL=outer nuclear layer. Scale bar: 100μm.

Figure 2-16. Cellular localization of CACNA2D1 in a human donor eye with no
diagnosis of ocular diseases
Sections from the anterior chamber angle and retina were labeled with antibodies against
CACNA2D1. TO-PRO-III iodide staining labeled nuclei of all retinal cells (blue).
Abbreviations: TM=trabecular meshwork; CB=ciliary body; CM=ciliary muscle; SC=
schlemm's canal; GCL=ganglion cell layer; INL=inner nuclear layer; ONL=outer nuclear
layer. Scale bar: 20μm.
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and reproduced over time. Using the BXD RI genetic reference population, we found that
IOP is highly heritable and variable, there was no gender influence in IOP at 9.1-13
months.
To determine which candidate genes modulate IOP in the eye, we performed
simple interval mapping. Our mapping studies in BXD mice indicate a single highly
genome wide significant QTL on Chr5. Variation in IOP in the BXD family maps to Chr
5 with a LOD of 4.0 and a 1.5 LOD confidence interval from 14.2 to 18.8 Mb (Pclo to
A921504A21Rik). The effect size is +1.0 mmHg/per B allele. We pursued second strategy
of Pearson and partial correlation analyses to corroborate the findings of our QTL
analysis for Chr5. These results suggested that within this strong eQTL reside some
transcripts that predominantly regulate IOP. We focused on one positional and
biologically relevant geneCacna2d1located on Chr5 QTL peak. Cacna2d1 is the
best candidate and is cis-regulated in BXD retinal data sets. This gene has shown to play
key roles in modulating calcium uptake which is crucial for IOP in the eye (124). Tyrp1
and Gpnmb gene mutations have been well known to develop iris transillumination defect
in DBA/2J mice. However, based on our correlation analysis and previously published
paper there was no correlation between the expression of these genes and IOP. Moreover,
IOP did not map to either the Tyrp1 or Gpnmb locus (119).
Genetic variations are a major factor for inter-individual differences in disease
susceptibility and response to environmental exposures. The great majority of DNA
polymorphisms consist in SNPs. Most SNPs manifest in introns which may have no
effect on the individual phenotypes. However, SNPs, though rarely being directly
pathogenic, are frequently correlated to the occurrence of multigenic diseases. Both in
mouse and humans Cacna2d1 has hundreds of SNPs and insertions/deletions, which
makes it highly polymorphic. In humans, CACNA2D1 also contained a SNP with a p
value reaching significance at the individual gene level in the GLAUGEN and
NEIGHBOR human GWAS studies of POAG and IOP (SNP rs4732474, p=0.0075).
Recently, a GWAS of Beaver Dam Eye Study revealed 7 regions of interest modulating
IOP. One of the regions of interest is Chr7 which corresponds to CACNA2D1 gene and
this region has suggestive association with IOP (11). Another study has shown human
Chr 7 (i.e., 7q35-q36) to be associated with pigment dispersion syndrome (125). A
common variant mapping to another calcium channel subunitCACNA1A, is associated
with susceptibility to exfoliation syndrome (126). In this disease, there is a build-up of
extracellular matrix deposits and pigment in the trabecular meshwork which can impede
the drainage of AH from the eye thus resulting in elevated IOP and glaucomatous optic
neuropathy (126). This provides further evidence support to our hypothesis that
CACNA2D1 may modulate structure or function of calcium channels and contribute to
modulation of IOP in glaucoma. Our immunohistochemistry data demonstrated that
CACNA2D1 is localized in the ciliary body, trabecular meshwork and ciliary muscle as
well as in the RGC bodies and axons. This observation was consistent in both mouse and
human eyes. An interesting implication of this observation is that CACNA2D1 might be
modulating IOP via the AH dynamics and is neuroprotective as well, although the
mechanism by which this occurs is not known.
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CACNA2D1 encodes for the alpha2 delta1 subunit of the type L-type voltagedependent calcium channel. Calcium channels are responsible for the transport of calcium
ions across cell membranes and play a key role in a cell’s ability to generate and transmit
electrical signals. Calcium channels are ubiquitous and are responsible for the transport
of calcium ions across cell membranes which plays a key role in a cell’s ability to
generate and transmit electrical signals. They play important physiological roles in
modulating the calcium balance in various tissues (121). In the eye, calcium plays a
critical role in modulating the cleavage of calcineurin in response to elevated IOP, which
inhibits pressure-induced RGC axon loss (127). In addition, calpains activate cyclin
dependent kinase 5, which has also been implicated in POAG (128). Mishandling of
intracellular calcium by glaucomatous trabecular meshwork cells may also contribute to
its failure, leading to increased AH outflow resistance and elevated IOP (124). Excessive
calcium influx is a major player of retinal cell death and a hallmark of pathological
processes activated by retinal injury and disease (129). RGC loss due to dysregulated Ca
channel signaling has been attributed to glutamate excitoxicity mediated by
overstimulation of NMDA receptors, (130), activation of Ca2+ permeable TRP channels
(131), defective calcium buffering stores (for example, mitochondrial dysfunction) (132),
and excessive release of nitric oxide (133). Since functional deficits can occur early in the
progression of glaucoma and other optic neuropathies, targeted Ca channel blockade may
have a role to play in how optic neurpathies are treated. Understanding the role of
CACNA2D1 in RGCs will provide a platform for future experiments investigating their
contribution in retinal injury models. Because calcium channels play a role in the
pathophysiology of glaucoma, systemic calcium channel blockers (CCBs) have been
evaluated in a limited number of studies as plausible therapies for POAG (134).
However, the results have been inconsistent, with some studies demonstrating that CCBs
are highly effective in lowering IOP, protecting ganglion cells, increasing ocular blood
flow and improving visual function, while others fail to replicate those results (134). It is
possible that because CCBs target calcium channels, which are highly polymorphic, they
will only be effective on a subset of the population.
Our study provides the first candidate geneCACNA2D1, to explain variation in
IOP by combining the power of mouse quantitative genetics with human GWAS studies.
This novel finding will lead to the development of new IOP-lowering therapy. In future,
similar studies would enable us to identify glaucoma-associated genes and how these
genes can be validated as functional targets, and how this will bridge the gap between
data generation and effective drug target identification.
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CHAPTER 3. MULTIPRONGED APPROACH TO IDENTIFY AND
VALIDATE A NOVEL UPSTREAM REGULATOR OF SNCG IN MOUSE RGC*
Introduction
Glaucoma is the world’s leading retinal neurodegenerative disease that causes
irreversible vision loss (135). Degeneration of RGC somas and their axons is a hallmark
of its pathophysiology. Because it is a multifactorial disease, the degeneration of the
RGC can be influenced by multiple affecters including physiological stress (i.e. oxidative
stress, neurotransmitter toxicity (136), and/or ER stress-related chaperone proteins (137,
138). Members of the synuclein family of proteins are chaperone molecules
predominantly expressed in neurons (139). In diseases such as Alzheimer’s and
Parkinson’s, mutant synucleins are key components of pathological inclusions (140, 141).
Among the three known isoforms (, and ), a reduction in the expression level of synuclein (SNCG) in the retina and optic nerve head have been reported in glaucoma
patients (139, 142). Recent studies have demonstrated a direct correlation between the
reduced expression of Sncg mRNA and the loss of RGCs in various animal models of
glaucoma (143). Collectively, these studies suggest that loss of SNCG is a putative
marker of RGC degeneration, yet the molecular targets and biological relevance of
aberrant SNCG expression remains largely unknown.
In the present study, we used C57BL/6J and DBA/2J mice, as well as the BXD RI
family as a collective genetic reference panel to determine which gene(s) regulate Sncg
expression in murine RGCs. We have also compared the localization pattern of Sncg and
its upstream modulator in mouse and human donor retinae using immunohistochemistry.
Using flow cytometry-based sorting, we isolated enriched RGCs and performed
knockdown studies to validate our findings. The outcomes of our investigation may
provide clues to understanding the molecular mechanisms that account for the
degenerative changes in RGCs in glaucoma (Figure 3-1).
Methods
Human donor eyes
Human donor eyes were collected in accordance with the tenets of the Declaration
of Helsinki and approved by University of Tennessee Health Science Center (UTHSC)
Institutional Review Board (IRB). A human donor eye with a clinical diagnosis of
glaucoma (age 67 years; female) and an eye from an age-matched control (with no

*

Reprinted with permission from John Wiley & Sons. Chintalapudi SR, Morales-Tirado VM, Williams
RW, Jablonski MM. Multipronged approach to identify and validate a novel upstream regulator of Sncg in
mouse retinal ganglion cells. FEBS J. 2016 Feb;283(4):678-93. doi: 10.1111/febs.13620. Epub 2016 Jan
18. PubMed PMID: 26663874.
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Figure 3-1.

Illustrated summary

A combined study using systems genetics with flow cytometry and gene silencing to
identify and verify the genetic regulation of Sncg in primary RGCs. This study provides
clues to better understanding of disease mechanisms in glaucoma.
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history of eye disease; age 83 years; male) were obtained from the Mid South Eye Bank
and the Lions Eye Bank of Oregon in compliance with the Eye Bank Association of
America's (EBAA) Medical Standards and Government Regulation. Both donors were
free of sepsis and potentially transmissible disease. There was no evidence of high-risk
behavior, HIV or hepatitis. Donor eyes were fixed in formalin within five hours of
enucleation. The anterior segment structure was removed from both eyes and the fundi
were photographed. Full thickness biopsies of the temporal retina of each eye were
removed with a 5-mm diameter punch (Miltex, PA, USA). Retinae were carefully
dissected away from the retinal pigment epithelium, choriocapillaris and sclera.
BXD strains
A total of 73 strains of mice at approximately 8 weeks of age, including 69 BXD
RI strains, parents and F1 crosses were used in this study. Both sexes were equally
represented (117). All procedures involving mice were approved by the Animal Care and
Use review board of UTHSC and followed the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research in addition to the guidelines for laboratory animal
experiments (Institute of Laboratory Animal Resources, Public Health Service Policy on
Humane Care and Use of Laboratory Animals). Animals were housed under cyclic light
(12 hour on: 12 hour off) with 35% humidity in a specific pathogen free environment at
UTHSC. In our immunohistochemical analyses, a female BXD66 mouse aged ~12
months are used as a model of glaucoma due to their elevated IOP (18.501.47 mmHg;
unpublished observation but available on www.GeneNetwork.org) and high degree of
optic nerve damage inclusive of many degenerating axons and gliotic scarring that are
apparent on cross sections (unpublished observation but available on
www.GeneNetwork.org).
HEI Retina Database
The HEI Retina Database contains the data analysis of 346 Illumina Sentrix®
Mouse Whole Genome-6 version 2.0 arrays (Illumina, San Diego, CA). This database
contains the retinal transcriptome profiles of 80 strains of BXD mice aged between 2 and
4 months (117). We used the ‘Normal HEI Retina Dataset’ that is available on
GeneNetwork (www.genenetwork.org) to perform QTL analysis and define genetic
networks. This data is globally normalized to produce arrays that have a mean of 8 and a
standard deviation of 2.0 (70, 71). The GEO Dataset generated by Dr. Simon John and
colleagues at the Jackson Laboratory (NCBI accession number GSE26299; Affymetrix
platform; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26299) was
normalized in the identical manner and uploaded onto GeneNetwork. This dataset was
derived from retinae of DBA/2J mice with varying degrees of glaucomatous optic nerve
damage (38).
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eQTL mapping and heritability calculation
Simple interval mapping was carried out using the WebQTL module on
GeneNetwork to identify any significant eQTL(s) that modulate Sncg expression.
Genome wide significance levels were estimated by performing 2000 permutations. To
determine how much of the variation in Sncg expression across the cohort was due to
genetic effects, we calculated the heritability of Sncg using our published methods (59,
69, 82){Lu, 2011 #261;Lu, 2011 #204;Swaminathan, 2013 #100}.
Identification of candidate gene(s)
The partial correlation feature on GeneNetwork was used to identify any
candidate gene that modulates Sncg expression in retina. A partial correlation is defined
as the relationship between a primary variable and a target variable, while controlling for
one or more other variables (120). In this case, the correlation between the expression of
Sncg (primary variable) and the expression of candidate regulatory gene within the retina
database (target variables) was measured after mathematically controlling for the
markersrs8242766 (Chr1 at 172.981863) and rs4136041 (Chr1 at 177.366982)that
straddle the trans-eQTL that was identified using simple interval mapping. By holding
constant the genetic variation of this region, any residual biological variation more
accurately reflects the correlation between the expression of the Sncg and the candidate
regulatory gene(s). In essence, genes with false positive correlations are removed from
the list of potential candidate modifiers.
Immunohistochemistry
Human and murine retinal sections embedded in low melting point agarose were
prepared following our published methods (144). Briefly, tissue sections were blocked
with 10% goat serum and permeabilized with 0.1% Triton X-100. Anti-prefoldin 2
(PFDN2; goat polyclonal IgG, Catalog number: sc-19834; Santa Cruz Biotechnology)
and anti-gamma synuclein (SNCG; rabbit polyclonal IgG, Catalog number: GTX110483;
GeneTex) were used per manufacturers conditions. Appropriate Alexa Fluor-tagged
secondary antibodies (1:200; Invitrogen) and TO-PRO3 iodide (1:4000; Invitrogen) were
used to indicate the presence of the antigens of interest and nuclei, respectively. Sections
were viewed and images were obtained using a Nikon C1 confocal microscope within the
Imaging Core Facility in the Hamilton Eye Institute. All microscope settings, including
laser levels and gain, were held constant to allow for relative comparisons of signal
intensity within and between experiments.
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Enrichment of primary murine RCGs
Cell suspension of retinae cells
C57BL/6J mice (80 mice at 5-8 weeks of age) were sacrificed by cervical
dislocation followed by enucleation. Collected retinae were dissociated using enzymatic
digestion containing papain (15 IU/mL papain, 5 mM L-cysteine and 200U/mL DNase I)
in PBS. Enzymes were inactivated by the addition of PBS/10% fetal bovine serum (FBS;
Hyclone Laboratories, Inc.). The cell suspension was filtered through a Falcon 70 µM
nylon strainer (BD Biosciences, San Jose, CA) and centrifuged at 1300 RPM for 5
minutes at RT. Cells were resuspended in PBS/1% FBS and kept on ice until ready to
use. Cell viability was assessed by trypan blue exclusion (145).
Cell labeling
We used a 1:100 solution of an amine-reactive dye, Zombie Aqua (BioLegend),
diluted in PBS to discriminate between live and dead cells. Prior to immunolabeling, cells
were treated with 5 µL of anti-CD16/32 (FcR II/III block, BioLegend) to minimize nonspecific binding of antibodies. CD16/32 are also known markers for monocytes and
macrophages. Aliquot of unlabeled retinal cells were used as negative control to
determine the degree of autofluorescence and to control for voltages. The following
isotype controls were used to confirm the specificity of primary and secondary
antibodies: mouse IgG1 (clone MOPC-21, BioLegend) PE-Cy7, AF700, FITC PerCPCy5.5 and rat IgG2b (clone RTK4530, BioLegend). The AbC Anti-Mouse Bead Kit
(Life Technologies, Carlsbad, CA) was used as an instrument calibration and singlefluorochrome reference. The following primary antibodies were used to label cells for 30
minutes on ice: anti-CD90.1 PerCP-Cy5.5 (Thy1.1, clone OX-7, Catalog number:
202516, BioLegend; exhibits no cross-reactivity with CD90.2) and anti-CD90.2 Alexa
Fluor-700 (Thy1.2, clone 30-H12, Catalog number: 105320, BioLegend; exhibits no
cross-reactivity with CD90.1) as a Pan-Thy1 marker; and anti-CD48 PE-Cy7 (clone
HM48-1, Catalog number: 103424, BioLegend). Cells were enriched by FACS using a
BD Biosciences FACSAria Cell Sorter (BD Biosciences).
Sorting strategy
Live cells were gated by Zombie Aqua exclusion followed by Pan-Thy1
positivity. Live PanThy1+ cells were selected based upon negative CD48 expression. The
collected population of RGCs had the following phenotype: Live PanThy1+CD48neg cells.
Flow cytometry analyses
Intracellular straining
Cells were fixed for 1hr at 4°C using BD Cytofix/ Cytoperm™ Buffer (BD
Biosciences). Anti-gamma synuclein (dilution: 1:100; GeneTex Inc.) and anti-prefoldin 2
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(dilution: 1:100; Santa Cruz Biotechnology, San Diego, CA) antibodies were diluted in
permeabilization buffer and incubated with cells for 1hr at 4°C. Alexa Fluor-568 goat
anti-rabbit IgG or Alexa Fluor-488 donkey anti-goat IgG (Molecular Probes) were used
as secondary antibodies. Cells were kept in PBS/1%FBS until ready for analysis. Data
acquisition was performed on a BD LSRII Flow Cytometer (BD Biosciences) and
analyses were performed using FlowJo vX10.0.6 (Tree Star, Inc., Ashland, OR).
Cell proliferation studies
Sorted, enriched-primary RGCs were kept either for 4 hours or overnight at 4C
to restore the integrity of the cell membrane to ensure that cells were healthy prior to
further treatments. Enriched RGCs were re-suspended in PBS at a concentration of
5x106 cells/mL and labeled with 1 μM CFSE in PBS/1% FBS for 5 min at 37°C (146).
Cells were quenched three times for 10 minutes on ice bucket in 20 mL volume with cold
media-containing 10% serum. Labeled enriched RGCs (1x105 per well) were cultured in
96-well bottom plates for 48 hours at 37°C. At 0 and 48 hours, cells were harvested,
washed and analyzed. Acquisition proceeded using a BD LSRII Flow Cytometer
equipped with 4-lasers (BD Biosciences, San Jose) and analyses were performed using
FlowJo software (Tree Star, Inc., Ashland, OR), Cell Proliferation application. A
reduction in median fluorescent intensity (MFI) is indicative of mitotic activity.
RGC culture
The culture conditions developed Alissa Winzeler and Jack T. Wang (147) was
followed for the maintenance of sorted mouse RGCs in monolayer culture in a 96 well
plate. The cells were cultured in absence of serum, as the factors in serum are not well
defined and can vary widely between sample batches. Also, presence of serum in culture
has the potential to alter cellular responses dramatically. The medium contained
Dulbecco's modified Eagle's medium, Neurobasal medium, plus insulin (5g/mL),
progesterone sodium pyruvate (110 g/mL), penicillin (100U/mL), streptomycin
(100U/mL), thyroxine (T3; 40 ng/mL), L-glutamine (292 g/mL), NS21 supplement
(1X), N-acetyl-L-cysteine (NAC; 5 g/mL). Additional serum-free supplements were
added to further promote optimal RGC survival, this included Bottenstein-Sato
supplement (SATO; 1X). SATO was prepared by combining BSA (10mg/mL),
transferrin (10mg/mL), putrescine (1.6mg/mL), progesterone (6 g/mL), sodium selenite
(4g/mL). Additional trophic factors were also added to promote RGC health and
survival, these include- brain derived growth factor (BDNF; 50 g/mL), ciliary
neurotrophic factor (CNTF; 10 g/mL) and forskolin (4.2 mg/mL). Seeding densities
ranged from 40,000-60,000 cells/well. Cultures were incubated at 37°C in a humidified
atmosphere containing 10% CO2 and 90% air.
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siRNA transfection in primary RGCs
Mitotically active RGCs were cultured in 96 well plates for 24 hrs in RGC culture
media (147) after which the media was replaced with Accell delivery media (Dharmacon)
containing SMARTpool siRNA targeting mouse Pfdn2, a pool of 4 different siRNAs
targeting the gene to increase the potency (Target sequence 1:
GCAAAGAACUGAACGAAUU, Target sequence 2: UGAUUAAAUGUUUUGGUCA,
Target sequence 3: GAUUCCCACUUGUAAUUUC, Target sequence 4:
GGACUGUCAAAGAAGUGCU; Cat no: E-062703-00-0005; Dharmacon) or a nontargeting GFP fluorescent siRNA (Cat no: D-001950-01-05; Dharmacon) at a final
concentration of 1 μM according to the manufacturer’s protocol. Transfected cells were
cultured at 37°C for 48 hrs. Assessment of live cells after siRNA transfection was
performed by labeling cells with a 1:100 solution of an amine-reactive dye, Zombie
Red (BioLegend) diluted in PBS to avoid spectral overlap with GFP (emission:
emission 624 nm). Cells were incubated for 20 minutes at RT followed by two washes.
Finally, cells were suspended in PBS/1%FBS prior to analysis.
RNA isolation, cDNA synthesis and quantitative polymerase chain reaction
RNA isolation
RNA from 1.0 x 106 retinae cells was extracted using the Qiagen® miRNeasy
Mini Kit (Qiagen, Valencia, CA) per manufacturer’s protocol. Briefly, cells were lysed
by using a pipette, prior addition of chloroform and a series of alcohol induced
precipitation. The extract was passed through a spin column followed by on-column
DNase digestion to increase purity and yield. RNA purity and concentration was assessed
by analysis on NanoDrop Spectrophotometer. RNA used for cDNA synthesis met the
following requirements: A260:A230 ratio greater than 1.7; A260:A280 ratio between 1.8
to 2.1.
cDNA synthesis
Genomic DNA elimination and First-Strand cDNA synthesis were performed
using SuperScript® VILO™ cDNA Synthesis Kit (Life Technologies). Briefly, 70 ng of
RNA were combined with VILO™ Reaction Mix and Enzyme Mix using the following
conditions: 25C for 10 minutes, 42C for 60 min and 85C for 5 minutes. For preamplification of cDNA, the RT product was pre-amplified for Sncg and Pfdn2 genes
using TaqMan® Gene Expression Assays and TaqMan® PreAmp Master Mix as per
manufacturer’s protocols (Life Technologies Inc., Applied Biosystems). The preamplified cDNA was diluted with 1x TE (Tris/EDTA) at a 1:5 ratios and 2.5 μl of the
cDNA was used in each well for qRT-PCR reactions.
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qRT-PCR reaction
The following amplicons were used for the qRT-PCR reaction: Sncg,
Mm00488345_m1; Pfdn2, Mm00448103_m1; and Gapdh, Mm99999915_g1 (Life
Technologies). The ready-to-use TaqMan® Universal Master Mix II with UNG (Applied
Biosystems) contained AmpliTaq Gold® DNA Polymerase, dNTPs , ROX™ Passive
Reference, optimized buffer components. Reactions were run on a Roche LightCycler®
480 Real-Time PCR system (Roche, Indianapolis, IN) in 96-well plate format with a 10
μL final reaction volume at Molecular Resource Center at UTHSC. All reactions were
performed in triplicates from three independent biological replicates. Relative
quantitation was performed using the comparative threshold (CT) after determining the
values of CT for the reference gene Gapdh and the target gene Sncg or Pfdn2 in each
sample. Rqwas calculated using Equation 3.1:
Rq= 2−ΔΔCT

(Eq. 3.1)

ΔCT= (CT target gene) – (CT reference gene)
ΔΔCT = (ΔCT treatment sample) – (ΔCT reference control sample)
Statistics
Data presented as mean ± SEM. One-way ANOVA with Tukey’s post hoc tests
(PRISM GraphPad) were used to determine statistical significance. Differences were
considered significant at p < 0.001.
Correlation comparison and gene ontology tree machine construction
A secondary goal of our investigation was to identify genes that were co-regulated
with Sncg and Pfdn2 and shared a functional relationship. As a first step in this process,
the transcript levels of our genes of interestSncg and Pfdn2were compared using
Pearson correlation with all 45,281 probe sets present on the Illumina V6.2 array. The top
500 genetically correlated genes in the retinal database were selected. To produce a set of
shared correlated transcripts, we selected all common transcripts of Sncg and Pfdn2
within the list of the top 500 correlates of both genes. After removing the transcripts with
genes with expression levels less than 7 based on the expression data normalization
process. The remaining list of 163 common correlates were analyzed by Gene Ontology
enrichment analysis WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt), as described
previously (69, 82). GO enrichment analysis allows users to input lists of highly
correlated genes through the web interface, identifies GO terms that are significantly
associated with the input gene lists, and visualizes the enriched GO terms in a directed
acyclic graph (DAG).
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Results
Identification of Pfdn2 as a candidate gene modulating Sncg expression in murine
RGCs
To identify the genomic regions that modulate Sncg expression in the retina, we
used a systems genetics approach using the Illumina Array data from murine retinae. On
the Illumina arrays, Sncg is represented by two probe setsILMN_2939277 and
ILMN_2598478that hybridize to nucleotides within exon 4 and 1, respectively. Both
probe sets map with significant likelihood ratio statistic (LRS) scores to the same location
on the minus strand on Chr 14 at 35.187676 Mb. Because the ILMN_2598478 probe set
reflected higher average expression levels, it was selected to represent Sncg in our
analyses. The expression of Sncg in the retina among BXD mice varied (Figure 3-2) with
BXD15 having the lowest Sncg gene expression of 12.650.03 (expression Log2  SEM)
and BXD61 having the highest at 14.470.10. The average expression among all BXDs
was 13.800.33. The parental lines, C57BL/6J and DBA/2J, had Sncg expression levels
of 13.750.15 and 14.270.09, respectively at 1-2 months of age (Figure 3-2; Appendix
B, Table B-1). The heritability of the variation in Sncg expression was 0.57. This result
demonstrates that 57% of the variation in Sncg expression was due to genetic effects; and
the remaining 43% was due to environmental influences. The six SNPs and two deletions
in Sncg (Table 3-1) likely contribute to the genetic component of the heritability. The
simple interval map shows a significant trans-eQTL for Sncg on distal chromosome 1
(Figure 3-3). The maximum LRS score of the locus was 34.1 Mb, which is equivalent to
a LOD ratio of 7.40. The confidence interval of this strong QTL extends from 171.5 to
183.5 Mb (Figure 3-3 inset).
To identify the candidate gene(s) that modulates the expression of Sncg in the
retina, we performed partial correlation analysis within GeneNetwork (Figure 3-4). A
partial correlation reflects the level of association between a primary variable (i.e., Sncg
expression level) and a target variable (i.e., upstream regulator of Sncg expression level)
after controlling for one or more variables (i.e., the genetic variability of the trans-eQTL
peak on Chr 1 (120). In our study, applying partial correlation analysis allowed us to
mathematically control for the LRS peak on Chr1 and identified a single gene candidate,
Pfdn2 (partial Pearson correlation value: r=0.656; p=3.73x10-13). No other genes in that
interval had significant expression levels and significant correlation values. This outcome
solidified Pfdn2 as the candidate upstream modulator of Sncg. On the Illumina array,
Pfdn2 is represented by one probe setILMN_129667that hybridizes to exon 4 (Chr1
at 173.286888 Mb on the plus strand). The expression level of Pfdn2 varied among the
BXD strains from a low of 12.490.10 in BXD13 to a high of 14.410.2 in BXD39, with
an average expression of 13.450.08 (Figure 3-5). The parental lines, C57BL/6J and
DBA/2J, had Pfdn2 expression levels of 13.630.21 and 13.840.23, respectively at 1-2
months of age (Appendix B, Table B-2). The heritability of the variation in Pfdn2
expression was 39% and the remaining 61% of the variation in the expression was due to
environmental influences. To determine if there was any association between Sncg and
Pfdn2 in healthy young adult mice eyes to performed Pearson correlation analysis. The
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Figure 3-2.

mRNA expression levels of Sncg across BXD strains and parental strains

Rank-ordered mean Sncg mRNA levels across the BXD recombinant inbred family. The expression of Sncg in the retina among BXD
mice varied with BXD15 having the lowest Sncg gene expression of 12.650.03 (expression Log2  SEM) and BXD61 having the
highest at 14.470.10. The BXD strains and parental strains are depicted in grey and black, respectively. Values denote normalized
relative mRNA expression levels on Log2 scale (meanSEM).
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Table 3-1.
Gene
I.D.
Sncg

Summary of candidate genes Sncg and Pfdn2
Location

Chr 14 @
35.187676 Mb

Max LRS Value
and
Location
34.3;
Chr1:174.792334

Probe set I.D. and
BLAT Specificity
ILMN_2598478
;2.5

Markers
Flanking
the Gene
rs13482135@
36.200742 Mb

Mean
Expression
Level
13.804

SNPs and Indels
 Six intronic SNPs
 Two deletions


Pfdn2

Chr 1 @
173.286888 Mb

12.8;
Chr5:85.890222

ILMN_1219667
;3.1
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rs3722740 @
173.679247 Mb

12.8

 48 intronic SNPs
 One 3’UTR SNP
 One synonymous SNP
in exon 4
(A→ A, gcA →gcG)
 Four insertions
 Six deletions

Figure 3-3.

QTL mapping of Sncg

A significant trans-eQTL for Sncg is present on chromosome 1 at 167-190 Mb. Red and gray horizontal lines dictate significant and
suggestive thresholds, respectively. The purple triangle indicates the location of Sncg within the genome. The insert depicts a zoomedin view of the trans-eQTL on Chr1, which shows the location of Pfdn2 within the LRS peak.
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Figure 3-4.

Partial correlation analysis

The screen shot depicts the partial correlation analysis using the tools available on GN. Select and add Sncg into the BXD Trait
Collection in addition to two SNP markers rs8242766 and rs4136041, which are located at the borders of the QTL on Chr 1 between
172 and 178Mb (the location of the trans-eQTLs).
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Figure 3-5.

Expression levels of Pfdn2 across BXD strains and parental strains

Rank-ordered mean Pfdn2 expression levels across the BXD family of mice. The expression level of Pfdn2 varied among the BXD
strains from a low of 12.490.10 in BXD13 to a high of 14.410.2 in BXD39, with an average expression of 13.450.08. The BXD
strains and parental strains are depicted in grey and black, respectively. Values denote normalized relative mRNA expression levels on
Log2 scale (meanSEM).
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expression levels of Sncg and Pfdn2 in the retinae of BXD mice aged 1-2 months were
positively correlated (Pearson correlation value: r=0.609; p=3.38x10-09; Figure 3-6A),
which demonstrates that the two genes co-vary in the healthy retina.
As DBA/2J mice age, retinal ganglion loss becomes prominent. To investigate the
relationship between Sncg and Pfdn2 in aged DBA/2J mice, we used a GEO dataset
generated by Howell et al. (38). As noted by the authors, their DBA/2J mouse panel
exhibited varying degrees of glaucoma-associated damage at 10.5 months including an
increase in IOP and optic nerve head damage. On the Affymetrix panel used by Howell et
al., Sncg is represented by one probe set, 1417788_at, which hybridizes to exon 1 of Sncg
(Chr 14 at 35.183635 on the minus strand). On the same Affymetrix array, Pfdn2 is
represented by two probe sets, 1421950_at and 1435620_at, which hybridize to the last
three exons and far 3’UTR, respectively. Because probe set 1421950_at hybridizes to
exons rather than a regulatory region, it was used as the single representation of Pfdn2
expression in our studies. The average expression levels of Sncg and Pfdn2 across the
glaucomatous DBA/2J mice were 10.000.85 and 11.000.22, respectively. A significant
variation in the expression of Sncg was noted among these mice, which ranged between a
low of 8.08 in a mouse with a high degree of glaucomatous damage and a high of 10.72
in a mouse with a low degree of optic nerve damage. Pdfn2 expression varied in an
inverse manner with an expression of 10.62 in a mouse with a low degree of
glaucomatous damage to 11.54 in a mouse with a high degree of glaucomatous damage.
The direct Pearson correlation between Sncg and Pfdn2 across the D2 panel was
significant (r=-0.819; p=1.09x10-14; Figure 3-6B).
Subcellular localization of SNCG and PFDN2 demonstrate cytosolic co-localization
in mouse and human RGCs
To compile additional evidence to support our hypothesis that Pfdn2 modulates
Sncg expression, we determined the subcellular localization of both proteins in retinae
from healthy mouse eyes using immunohistochemical analyses (Figure 3-7). SNCG was
strongly detected in GCL in the retinas of 3 month old mice indicating that SNCG
expression is limited to cells in the GCL (Figure 3-7A, B and C). PFDN2
immunofluorescence was ubiquitous in retina was deteched in NFL, GCL, IPL, OPL and
ONL (Figure 3-7D, E and F). The negative controls using only secondary antibody for
both SNCG and PFDN2 are shown in Figure 2G-I and 2J-L, we observed no cross
reactivity with specific antibodies used in this study. In these investigations, identical
procedures including confocal laser settings were maintained throughout to allow for
qualitative comparisons between samples. Cross sections of healthy retinae from both
mice (Figure 3-8A, B, C and D) and human (Figure 3-8I, J, K and L) illustrate colocalization of SNCG (red) and PFDN2 (green) in the cytoplasm of RGCs and also in the
NFL. In contrast, the sub-cellular localization and abundance of SNCG in retinae of
glaucomatous BXD66 mice was decreased compared to healthy mice (Figure 3-8E, F, G
and H). Similarly, there was an identical reduction in the intensity of SNCG labeling in
the retina from a human glaucoma patient (Figure 3-8M, N, O and P) compared to a
healthy control (Figure 3-8I, J, K and L). Changes were specific to SNCG
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Figure 3-6.
BXD mice

Pearson correlation between Sncg and Pfdn2 expression in retinas of

(A) The graph represents a strong positive correlation between expression levels of Sncg
and Pfdn2 (p=3.37x10-09) in the retina of young mice with no glaucomatous damage.
Numbers indicate BXD strains, and the parents. (B) The graph represents a strong
negative correlation between Sncg and Pfdn2 (p<10-14) is present in retinae from aged
DBA/2J glaucoma mice. Optic nerves from aged DBA/2J mice derived from the Howell
et al, data set had the following degrees of axonal damage: Severe (greater than 50%
axons lost, Δ); Moderate (10%–50% of axons lost, Θ); No/early 1 (no detectable damage,
); No/early 2 (no detectable damage, ); and Control (no glaucoma; 10.5-month-old
DBA/2J-Gpnmb+/Sj mice, ).
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Figure 3-7.

Detection of SNCG and PFDN2 in healthy mouse retina

(A-C) In healthy control mouse SNCG (green) immunoreactivity was detected in the
GCL. (D-F) PFDN2 (green) was ubiquitously expressed in all the retinal cells. To-PROIII iodide (blue) counterstained the nuclei. Merged images are shown in A and D. (G-I
and J-L) Negative controls show no non-specific labeling of the antibodies. NFL= nerve
fiber layer, GCL=ganglion cell layer, IPL=inner plexiform layer, INL=inner nuclear
layer, OPL=outer plexiform layer, ONL=outer nuclear layer. Scale bars: 10µm.
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Figure 3-8. Co-localization of SNCG and PFDN2 in healthy and diseased mouse
and human RGCs
(A-D) In a control mouse (C57BL/6) and (E-H) a mouse model of glaucoma (BXD66),
SNCG (red) was localized throughout the cytoplasm, nuclei and nerve fiber layer.
PFDN2 (green) was localized to RGC cytoplasm and the nerve fiver layer. To-PRO-III
iodide (blue) counterstained the nuclei. Merged images are shown in A and E. In a human
donor eye with no diagnosis of disease (I-L) and a donor with glaucoma (M-P), SNCG
localization patterns and relative levels were identical to those found in mice. Merged
images are shown in I and M. Arrows in E and M mark reduced expression of SNCG in
the glaucomatous retina. GCL=ganglion cell layer, NFL=nerve fiber layer. Scale bars:
10µm.
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immunoreactivity (Figure 6B, 6F, 6J, 6N), as we did not observe changes in PFDN2
levels between healthy and diseased retinae (Figure 3-8C, G, K and O). These data
demonstrate that SNCG expression is limited to RGCs, which corroborates with
previously published studies in RGCs, yet PFDN2 is expressed in RGCs as well as other
cells throughout the retina.
Quantitative and qualitative analyses of SNCG and PFDN2 in isolated RGCs
Using dissociated retinal cells and flow cytometry, we provide additional
evidence to support our hypothesis that both SNCG and PFDN2 are co-expressed in
RGCs. Each dissociated mouse retina yielded on average 5X1061.2 cells based on
trypan blue exclusion. Flow cytometry analyses revealed that we consistently obtained
greater than 952.4% live cells (Figure 3-9). Downstream analyses were performed
exclusively on live cells. To investigate the percentage of retinal cells that expressed both
PFDN2 and SNCG, we used intracellular labeling. Figure 3-10 (left panel) shows that
only a small percentage (<2%) of live retinal cells are SNCG+. We expected that the
percentage would be small considering SNCG is expressed solely by RGCs which
comprise ~0.5% of all retinal cells (148). In contrast, all live murine retinal cells were
positive for PFDN2, a ubiquitously expressed chaperone protein (Figure 3-10 middle
panel). Among experiments, we measured an average of 1000 and 1.50.4% of total
retinal cells that express PFDN2 and SNCG, respectively. Retinal cells probed
simultaneously with antibodies for both proteins showed that <2% of live retinal cells
have the PFDN2+SNCG+ phenotype (Figure 3-10, right panel).
Intracellular labeling using anti-SNCG and anti-PFDN2 antibodies allow for
robust identification of RGCs, but it renders them unviable for downstream investigations
because the cells are fixed and permeabilized as they become metabolically inactive. To
overcome this shortcoming, we isolated primary RGCs using FACS and cell surface
antibodies. As shown in Figure 3-11, we performed a positive selection using a Thy1+
(Pan-Thy1) antibody and a negative selection using a CD48 antibody to remove
monocytes, macrophages and microglia. To verify that the live Pan-Thy1+CD48neg cells
were RGCs, we performed intracellular labeling on a small aliquot, as detailed above.
Among the live retinal cells, 602.1% were Pan-Thy1+ (Figure 3-11, left panel) and
233.6% of them were CD48+ (Figure 3-11, middle panel). This positive and negative
selection strategy allowed us to enrich for RGC with a Live Pan-Thy1+CD48neg
phenotype. We further verified this phenotype using the SNCG intracellular marker and
demonstrate that 453.5% of enriched cells are immunopositive for SNCG. This
indicates that our enrichment strategy increases the number of RGCs 30-fold (45± 3.5%
vs 15±0.4%) compared to the number found within the retina (Figure 3-11, right panel).
Enriched RGCs with a Live PanThy1+CD48neg phenotype were maintained in
RGC media at 4°C overnight after sorting to allow for restoration of the plasma
membrane. We then labeled cells with 1 M CFSE to determine cellular proliferation and
quantified CFSE fluorescence over time to determine cell viability and proliferative
status so they could be used in downstream testing (Figure 3-12). Flow cytometry
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Figure 3-9. Dissociated retinal cells were labeled with Zombie Aqua™ for
live/dead cell analysis
Top Panel, representative pseudocolor plot showing Zombie Aqua+ cells, which depicts
dead cells. Bottom Panel, in our cell suspension approximately 97.5% of cells are alive,
based on exclusion of Zombie Aqua™ dye.
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Figure 3-10. Histogram analysis showing the percentage of retinal cells labeled
with anti-SNCG anti-PFDN2 antibodies
Pseudocolor plot shows <2% of retinal cells are positive for both SNCG and PFDN2.

Figure 3-11. Cell enrichment strategy
Cells were positively selected based on Pan-Thy1 (Thy1.1 and Thy1.2 antibodies)
staining. The Pan-Thy1+ population was negatively selected for CD48 to have a final
phenotype of Live Pan-Thy1+CD48neg cells. An aliquot of the sorted cells was evaluated
for intracellular SNCG labeling, which exhibit 41% positivity.
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Figure 3-12. Cellular proliferation was measured by CFSE labeling
Distribution shift indicate that sorted Pan Thy+CD48neg cells undergo cell division.
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analysis revealed that RGCs were alive and underwent mitotic division (Figure 3-12),
thus making them competent for mechanistic studies.
siRNA mediated knockdown of Pfdn2 significantly reduced the expression of Sncg
in enriched RGCs
To investigate whether the enriched RGCs are suitable for siRNA transfection,
cell survival was measured by using Zombie Aqua™ viability dye (BioLegend, San
Diego, CA) after siRNA transfection. No significant difference (p>0.05) in viability was
observed between the mock-transfected cells and those transfected with control siRNA or
Pfdn2 siRNA (Figure 3-13A). To directly investigate if Pfdn2 modulates Sncg
expression in enriched RGCs, the levels of Pfdn2 and Sncg mRNA transcripts were
measured 48hours after transfecting the cells with Pfdn2 siRNA. Quantitative
transcriptional analyses demonstrate that both Sncg and Pfdn2 are expressed in enriched
primary RGCs (Figure 3-13B). A significant knockdown of Pfdn2 expression (61%
reduction; p≤0.001) was observed in the cells transfected by Pfdn2 siRNA compared to
cells exposed to control siRNA. Furthermore, knockdown of Pfdn2 expression using
siRNA resulted in a significant reduction in the expression of Sncg mRNA compared to
samples treated with control siRNA (57% reduction; p≤0.001) and samples without any
siRNA treatment (89% reduction; p≤0.001) (Figure 3-13B), demonstrating that
decreasing Pfdn2 expression levels caused a significant reduction in Sncg expression in
primary enriched murine RGCs. These results strongly suggest that Pfdn2 modulates
Sncg in RGCs.
The transcriptional downregulation of Pfdn2 reduced PFDN2 and SNCG proteins
coded by Pfdn2 and Sncg, respectively. Flow cytometry analyses (Figure 3-13C) after
cell transfection resulted in a significant reduction in the number of PFDN2+ cells
(18.8±8.2% when transfected with Pfdn2 siRNA compared to 39.1±3.8% when
transfected with Control siRNA, p=0.049). Under this same experimental condition, we
also found a statistically significant reduction in the percentage of enriched RGCs that
were immunopositive for SNCG (10.2±10.1% when transfected with Pfdn2 siRNA
compared to 41.7±0.6% when transfected with Control siRNA, p=0.047). Collectively,
our results show that knockdown of Pfdn2 using siRNA results in a decrease in both the
amount of Sncg transcript and the number of SNCG+ cells.
Network enrichment highlights the involvement of mitochondrial function
As a next step in our investigation, we identified the top 500 genes with variation
in expressions levels that were correlated with changes in Sncg or Pdfn2 expression
levels. The comparison of shared correlates of Sncg and Pfdn2 generated a list of 163
genes (Figure 3-14). This list was submitted for GO tree enrichment analysis and a
directed acyclic graph was generated that grouped the transcripts according to molecular
function. Ten of 32 (31%) categories in the graph were statistically over-represented in
the GO tree generated from the 163 shared correlates. Five out of eight (62%) clusters
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Figure 3-13. Pfdn2 knockdown inhibits Sncg expression in enriched primary RGCs
(A) Viability of retinal cells defined by Zombie Aqua™ after control siRNA and Pfdn2 siRNA transfection for 48 hours is similar to
untreated cells (p>0.05). (B) Transcriptional analyses for Sncg and Pfdn2 in primary mouse RGCs demonstrate a significant
downregulation of Sncg mRNA after Pfdn2 siRNA treatment (*p<0.001). There is a significant difference between the level of Pfdn2
expression in the control siRNA treatment group and the Pfdn2 siRNA treatment group (# p<0.001). There is also a significant
difference between the level of Sncg expression in the control siRNA treatment group and the Pfdn2 siRNA treatment group (*
p<0.001). Results are presented as a fold change after normalizing to the level of Gapdh mRNA. (C) Protein analyses by flow
cytometry show a significant reduction in the percentage of enriched RGCs that were immunopositive for SNCG and PFDN2 after
Pfdn2 siRNA treatment. There is a significant difference between the number of cells that are immunopositive for PFDN2 (# p<0.05)
and SNCG (* p<0.05) after transfection with Pfdn2 siRNA. Specific isotype controls were used to distinguish between positive and
false positive cells. Results are shown as means ± SEM from three independent biological replicates performed in triplicate.
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Figure 3-14. Venn diagram summarizing number of gene transcripts with
expression levels that are correlated with Sncg and Pfdn2 expression levels, along
with the number of shared correlates between the two groups
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contained genes related to mitochondrial function: “Oxidoreductase activity” (11 genes);
“Hydrogen ion transmembrane transporter activity” (4 genes); and “Structural constituent
of ribosome” (4 genes); “NADH dehydrogenase activity” (2 genes); and “Cytochrome-c
oxidase activity” (2 genes) (Figure 3-15; Appendix B, Table B-3 to B-7). The gene
products encoded by these transcripts are present in mitochondria, and are involved in
maintaining the potential difference across the inner mitochondrial membrane
maintaining normal physiological function (Figure 3-16) (149-169).
Discussion
In this investigation, we have combined cutting edge methodologies of systems
genetics, bidirectional studies using multiple species, meta-analyses,
immunohistochemistry, FACS sorting and gene knockdown studies to identify and
validate the identity of a genetic modulator of Sncg, a gene that has been previously
implicated in RGC death in glaucoma. Our investigation identified Pdfn2 as an upstream
regulator of Sncg in RGCs. In healthy retinae, the protein levels of both genes are
significantly correlated in a positive manner. In addition, they are co-localized in the
cytoplasm of RGCs and in the nerve fiber layer. Targeted downregulation of Pdfn2 in an
enriched population of murine RGCs resulted in both the suppression of Sncg mRNA and
also in the number of enriched RGCs that express SNCG. We have further demonstrated
using two mouse glaucoma models–BXD66 and DBA/2J, and the retina from a human
donor glaucoma patient, that the relationship between the two genes is modified in the
diseased state. Specifically, in glaucoma, the relationship between the genes appears to
have changed to an inverse relationship with reduced Sncg levels as the disease
progressed. SNCG protein levels also dropped to nearly negligible levels in RGCs from
subjects with advanced disease, while PDFN2 levels have remained steady.
Previously, linkage analyses and clustering methods have been used to identify
candidate genes, such as complement component 1a (C1qa), that were associated with
glaucoma in BXD strains (170). In our investigation, we went a step farther and
utilized partial correlation analysis to solidify the relationship between Sncg and Pfdn2 in
the mouse retina. The statistically significant partial correlation between Sncg and Pfdn2
reflects gene–gene interactions, as well as a regulatory relationship between the genes.
The partial correlation approach has successfully been developed and applied to
transcription data from yeast (171), Arabidopsis thaliana (172 ), HeLa cells (173), and
breast cancer tumors (174). To our knowledge, it has not previously been used to study
the interactions between two genes in the mouse retina.
Sncg has been suggested to be a marker for glaucoma due to the association
between RGC degeneration and the loss of Sncg mRNA and protein expression in both
human glaucoma patients and animal models of glaucoma (139, 142, 143). In
neuroretinal cells, SNCG plays an essential regulatory role in resistance to stress, and
neuroprotection (175 ). Another report demonstrated that a reduction in SNCG protein
levels initiates an apoptotic death cascade due to the dephosphorylation of BCL2-binding
protein (176). In addition, the loss of Sncg correlates with increased RGC death as shown
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Figure 3-15. Gene ontology analysis of the shared correlates of Sncg and Pfdn2 are
presented
Categories that are statistically over-represented are presented (adjusted p=5.9x10-2 for
all groups). Categories indicated with a red bar indicate mitochondria-associated genes
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Figure 3-16. Gene ontology analysis of the shared correlates of Sncg and Pfdn2
Categories that are statistically over-represented are presented in (adjusted p=5.9x10-2 for
all groups). Categories indicated with a red boxes indicate mitochondria-associated genes.
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in DBA/2J mice (143). Apart from its neuroprotective role, SNCG acts as a molecular
chaperone (177) by interacting with myocilin, a glycoprotein that when mutated is
associated with glaucoma (178). Collectively, the literature suggests that SNCG plays a
critical role in RGC health, yet the regulation of this gene had not yet been previously
investigated.
PFDN2 is a ubiquitously expressed protein in the retina as a heterohexameric cochaperone that in eukaryotes and it is also a component of the prefoldin complex (179).
Of direct relevance to our investigation, prefoldins 1-6 are neuroprotective and they
specifically prevent the aggregation of misfolded proteins, such as αsynuclein (180,
181). When mutated, Pfdn2 is likely involved in the formation of toxic β-amyloid
oligomers that are a common pathology of multiple neurodegenerative diseases (182) In
addition, Lee et al., have reported that Pfdn5 is crucial for normal sensory and neuronal
development (183). Mutations in other family members, such as Pfdn3, cause structural
disorganization of neuronal microtubules and microfilaments (184). Several lines of
evidence suggest that the main cytoskeletal proteins, including microtubule-associated
proteins and neurofilaments, are not normally transported along the ocular axon stump of
degenerated RGCs, which leads to apoptosis (185). Strong immunolabeling of SNCG and
PFDN2 in the nerve fiber layer of both mouse and human retinae in our study suggests a
possible role of these genes in microtubule regulation or trafficking in axons of RGCs.
Pfdn2 is located in the QTL rich region (Qrr1) on Chr 1, which is a genomic
region of unusually high gene density and contains major regulatory QTLs for various
behavioral, metabolic, physiologic and immunological processes (179, 186, 187)
including diverse epileptic traits (188 ). The distal portion of Qrr1 is strongly implicated
in modulating RNA metabolism, translation, tRNA aminoacylation, and transportation of
transcripts into neuronal dendrites (186). Qrr1 also modulates behavioral alterations in
respect to activity and anxiety (189, 190). Physiologically relevant genes such as formin2 (Fmn2), regulator of G-protein signaling 7 (Rgs7) and a cluster of tRNAs are
modulated by the Qrr1 distal region. However, none of these genes had significant partial
correlation values with Sncg and therefore they were excluded from the list of candidate
upstream modulators of this Sncg.
In glaucomatous DBA/2J mice, we identified an inverse relationship between
Sncg and Pfdn2. Specifically, mice that have the highest degree of degeneration have the
lowest Sncg level, yet the highest level of Pdfn2 expression. Using both qualitative and
quantitative methods, we demonstrate that in compared to healthy individuals with no
disease, SNCG is reduced in the retina of glaucoma patients. These findings are shared by
both humans with a diagnosis of glaucoma and a novel BXD model of glaucoma. It is
plausible that in glaucoma that RGCs upregulate Pdfn2 in an attempt to increase Sncg
expression. Its known that glaucoma induces stress to the RGCs, which leads to damage
to proteins in the cells. Stress induced synthesis of chaperones is impaired in in diseases
such as glaucoma. It is plausible that reduction in Sncg expression in aging DBA/2J is an
effect of age-related changes associated with glaucoma, to protect the cells from damage
Pfdn2 expression upregulates to compensate for the loss of chaperone function in RGC.
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Due to the complex cellular heterogeneity of the retina, it is relatively difficult to
reliably obtain a pure RGC population from retina. In particular, the comparative analysis
of molecular regulation or profiles is hampered by the lack of an adequate methodology
for the selective purification of RGCs from retinae. I have addressed this caveat in
Chapter 4 of this dissertation. A representative histogram shows that using our
enrichment protocol 41% of the sorted live enriched RGCs were SNCG-positive.
Moreover, our CFSE results indicate that these cells are viable and are capable of
dividing for at least 48hrs under specific cell culture conditions. We have also been
successful in keeping enriched RGCs alive for upto 6 days. The cell culture conditions
that we used does not include serum. Presence of serum in culture has the potential to
alter cellular responses dramatically. Serum-free media has proven to be critical both in
addressing how RGCs behave independently of other signals and in identifying the
molecular signals that mediate specific neuronal–glial interactions in the CNS (191-195).
Addition of trophic factors such as BDNF, CNTF, and insulin which are usually made by
cells in contact with RGCs promote RGC health and survival. The present strategy allows
for the enrichment population of murine RGCs that retain the integrity of their proteins,
DNA and RNA for subsequent downstream biochemical and molecular analyses.
Using our enriched primary RGCs, we used a siRNA-based approach to
knockdown Pfdn2 gene expression and measure the effect upon Sncg expression. Our
data show that targeted siRNA successfully downregulated Pfdn2 by ∼61% p≤0.001 at
48 hour post transfection. Comparative gene expression analyses revealed an equally
effective downregulation of Sncg in enriched RGCs treated with Pfdn2- targeted siRNA.
Our data demonstrate that, Pfdn2 is upstream of Sncg and it directly modulates Sncg
expression in enriched mouse RGCs. The majority of the biological process categories
represented in the GO enrichment analysis from Sncg and Pfdn2 shared correlates are
associated with mitochondrial structure and function. RGCs are responsible for
transmitting visual information from the retina to the lateral geniculate nucleus. Due to
this large anatomical distance, RGCs must transport metabolites and organelles via
axonal transport, a process with a high-energy demand. Mitochondria play a key role in
the life and death of neurons. Any dysfunction of axonal transport or mitochondrial
function can have severe consequences on RGC function and viability (196, 197).
Additional studies show that mitochondria are a direct target of α-synuclein in
Parkinson’s disease (198), which lends support for our findings. Several lines of evidence
suggest that transport of mitochondria within a cell occurs by interactions with a variety
of cytoskeletal proteins which contributing to maintenance cellular physiology (199,
200).
In summary, our results show that genetic mapping and network modeling can be
combined with multiparametric flow cytometry and gene silencing to identify and verify
the genetic regulation of a retinal gene. Ours is the first investigation in which the
relationship between Sncg and Pfdn2 has been established in both the intact retina and in
enriched primary murine RGCs. The discovery of this relationship may help in guiding
studies that explore the disease mechanisms associated with altered protein transport and
folding in RGCs. In glaucoma the identification and confirmation of these two proteins in
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RGC health and disease holds great promise for developing molecular targets to slow
RGC damage, which in turn will preserve vision.
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CHAPTER 4.

ISOLATION AND VALIDATION OF PRIMARY MURINE RGCS
FROM HEALTHY AND DAMAGED RETINAE*
Introduction

Glaucoma is a complex multifactorial disease characterized by the progressive
dysfunction and loss of RGCs and associated visual field deficits. It remains a leading
cause of vision loss affecting 70 million people worldwide (201). In spite of notable
technical advances, the cellular mechanisms underlying their loss remain unclear. This is
in part due to the lack of standardized, reliable protocols to isolate large numbers of
highly enriched RGCs and/ or a RGC line for in vitro mechanistic studies (202, 203).
Identifying the genetic basis or cellular mechanisms causing RGC degeneration would be
the first step towards development of efficacious therapies to slow or reverse RGC
damage, in turn preserving vision. The lack of a validated RGC population represents a
large unmet need for the vision research community at large.
The isolation and enrichment of primary murine RGCs is essential for
investigating RGC responses to specific therapies in vitro. A number of challenges have
prevented progress towards the use of a homogeneous primary murine RGC population.
First, a major challenge lies on the scarce number of RGCs that can be isolated from
murine retinae (148, 204, 205). Second, current signature markers for the identification of
RGCs are intracellular markers (206-208), impeding the isolation of viable, metabolically
active cells downstream for in vitro studies. Third, current protocols are lengthy and
have not been standardized for the isolation of primary murine RGCs from dissociated
retinae. Barres et al. (209) adapted the immunopanning technique into a two-step process
to purify RGCs. The process includes depletion of macrophages and endothelial cells,
followed by positive selection of cells responding to anti-Thy1. Recently, Hong (210)
optimized a similar process that included positive selection of Thy1+ cells using magnetic
beads followed by cell sorting. Both approaches require lengthy isolations and their
yields are inconsistent. A commercial kit is available for isolating RGCs from retinae
(211), however, it has two major limitations: the kit is for exclusive use in rats, yet mice
are the primary animal model used in vision research; and the specificity of this kit for
RGCs is debatable, as amacrine cells could also be isolated with this method. In recent
years the use of Dynabeads or flow cytometry in conjunction with monoclonal antibodies
(212) or lectins (213) has provided powerful tools to improve the purity of isolated cells.
Flow cytometry, also known as FACS, is a powerful method that analyzes cell
suspensions and provides quantitative and qualitative data with a high level of sensitivity.
FACS cellular discrimination is based on physical properties such as surface area and the
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internal complexity or granularity of the cells (214). Multi-dimensional analysis, based
upon the expression of proteins on the cell surface as well as intracellularly, can be
performed by the combination of antibodies tagged with fluorochromes. Current FACSbased cell sorting techniques allow for the separation of up to four different cell
populations based on multivariate properties. Sorted cells can be collected and are viable
for downstream analyses.
In the present study, we developed a novel flow cytometry-based protocol to
generate a homogeneous RGC population from murine retinae. We employed a highly
stringent sort strategy coupled with qualitative PCR (qPCR) and intracellular staining
with RGC-signature markers to verify the purity and homogeneity of the enriched
population. Our isolation technique provides a powerful tool for vision research to assist
in the understanding of the molecular pathways and key players in preservation of RGC
function and health to develop novel therapies for vision loss (Figure 4-1).
Methods
Dissociation of murine retinae
Two hundred C57BL/6J mice between 5-7 weeks of age, 22 BXD66 mice ages 5
weeks (young) and >12 months (old) were used in this study. All procedures were
approved by the Institutional Animal Care and Use Committee (IACUC) review board at
the University of Tennessee Health Science Center (UTHSC) and followed the
Association for Research in Vision and Ophthalmology (ARVO) Statements for the Use
of Animals in Ophthalmic and Vision Research, in addition to the guidelines for
laboratory animal experiments (Institute of Laboratory Animal Resources, Public Health
Service Policy on Humane Care and Use of Laboratory Animals). Mice were sacrificed
by cervical dislocation followed by enucleation, as previously described in (215). Retinae
were dissociated using enzymatic digestion. The resultant cell suspension was filtered
using a Falcon 70m nylon strainer (BD Biosciences, San Jose, CA) followed by
centrifugation at 1500 RPM x 5 minutes at RT. Cells were resuspended in PBS/1% FBS
(Lonza, Walkersville, MD) and kept on ice until ready for use.
Flow cytometry analyses
Cell surface labeling
Cell viability was evaluated at the time of retinae cell dissociation. To ensure we
obtain live cells after sorting, we labeled the cells with Zombie Aqua™ (BioLegend, San
Diego, CA) a permeant dye to discriminate between live (negative for dye) and dead
(positive for dye) cells. Live cells were treated with 1.0g of anti-CD16/CD32 per
1.0x106 cells in 100L to block FcRII/III (clone 93; BioLegend), which minimizes nonspecific binding of the primary antibodies and in turn inhibits endocytosis, phagocytosis

70

Figure 4-1.

Illustrated summary

Loss of functional RGCs is an element of retinal degeneration that is poorly understood.
This is in part due to the lack of a reliable and validated protocol for the isolation of
primary RGCs. Here we optimize a feasible, reproducible, standardized flow cytometrybased protocol for the isolation and enrichment of homogeneous RGC with the
Thy1.2hiCD48negCD15negCD57neg surface phenotype. A three-step validation process was
performed by: (1) genomic profiling of 25-genes associated with retinal cells; (2)
intracellular labeling of homogeneous sorted cells for the intracellular RGC-markers
SNCG, BRN3A, TUJ1, and RBPMS; and (3) by applying the methodology on RGC from
a mouse model with elevated IOP and optic nerve damage. Use of primary RGC cultures
will allow for future careful assessment of important cell specific pathways in RGC to
provide mechanistic insights into the declining of visual acuity in aged populations and
those suffering from retinal neurodegenerative diseases.
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and antigen presentation due to FcR activation. The following primary antibodies were
used to detect surface antigens by incubating the cells on ice for 30 minutes: anti-CD90.1
PerCP-Cy5.5 (Thy1.1, clone OX-7, BioLegend, exhibits no cross-reactivity with
CD90.2); anti-CD90.2 Alexa Fluor-700 (Thy1.2, clone 30-H12, BioLegend, exhibits no
cross-reactivity with CD90.1); anti-CD48 PE-Cy7 (clone HM48-1, BioLegend, labels
monocytes and microglia); anti-CD15 PE (clone MC-480, BioLegend, labels amacrine
cells); and anti-CD57 (clone VC1.1, Sigma Aldrich, St. Louis, MO, also labels amacrine
cells). Because the anti-CD57 antibody was unconjugated, a Brilliant violet 421-tagged
secondary antibody (Life Technologies, Carlsbad, CA) was used to allow for sorting.
Sorting strategy
Cells were enriched by fluorescent activated cell sorting (FACS) using a BD
Biosciences FACSAria™ Cell Sorter equipped with 4-lasers (BD Biosciences, San Jose,
CA). In this investigation, we used the 488nm blue, the 630nm red and the 405nm violet
diode lasers. Dissociated cells were maintained at 4°C using a temperature controlled
sample injection and collection chamber. At the time of cell sorting, we used unlabeled
murine retinal cells as controls and individual samples were labeled with antibodies
specific for different retinal cell surface markers. We used AbC™ Total Antibody
Compensation Bead Kit (Life Technologies) to prepare single color controls using the
manufacturer's protocol. These are highly sensitive and efficient antibody capture beads
with a broad multispecies reactivity. To determine the efficiency of the sort, we took a
small sample of the eluted sorted sample followed by immediate FACS analysis.
Intracellular labeling
Dissociated cells labeled as detailed above followed by 1hr fixation at 4°C using
the BD Cytofix/ Cytoperm™ fixation/permeabilization solution (BD Biosciences) as in
(216, 217). Cells were incubated for 1hr at 4°C in the following antibodies that were
diluted in BD Perm/Wash buffer: anti-RBPMS (rabbit polyclonal IgG; Santa Cruz
Biotechnology, Santa Cruz, CA; 1:100 dilution); anti-SNCG (rabbit polyclonal IgG;
GeneTex, 1:100 dilution), BRN3A (goat ployclonal IgG; Santa Cruz Biotechnology;
1:100 dilution); and anti-TUJ1 (mouse monoclonal IgG2a; Covance; 1:100 dilution). The
appropriate Alexa Fluor 488 tagged secondary antibodies (1:200 dilution; Invitrogen)
were used to allow for data acquisition and analysis. Cells were kept in PBS/1%FBS on
ice until the time of analysis. Data acquisition was performed on a BD LSRII Flow
Cytometer (BD Biosciences) and analyses were performed using FlowJo vX10.0.6 (Tree
Star, Inc., Ashland, OR). To confirm results we performed additional data acquisition
using the Miltenyi Biotec MACSQuant® 10 Analyzer (Myltenyi Biotec, San Diego, CA).
Flow cytometry and confocal microscopy dual analysis
Labeled retinal cells were acquired based on area and aspect ratio, gating out cell
debris and cell aggregates from the analysis using the Amnis® FlowSight® Imager (EMD
Millipore, Amnis Division, Seattle, WA). Flow cytometry features include a violet (405
nm, 100 mW), blue (488 nm, 60 mW), red (642 nm, 100 mW), and SSC (785 nm, 8 mW)
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lasers. Data were analyzed in IDEAS software after compensation of single color control
samples using a compensation matrix. Confocal images were taken at 20x.
Gene analyses
RNA isolation and cDNA synthesis and pre-amplification of cDNA template
RNA from 5.0x105 sorted Live Thy1.2+CD48negCD15negCD57neg cells was
extracted following the Qiagen® miRNeasy Mini Kit (Qiagen, Valencia, CA)
manufacturer’s specifications. RNA concentration was assessed using a Nanodrop
Spectophotometer (Nanodrop, Wilmington, DE). cDNA was synthesized from RNA
using the SuperScript® VILO™ cDNA Synthesis Kit (Life Technologies). Following the
manufacturer’s instructions, we used 100ng of RNA for each reaction. Briefly, the preamplification reaction mixture was prepared using cDNA, TaqMan® PreAmp Master Mix
and the pooled primer mix listed in Appendix C, Table C-1. Pre-amplification: the
enzyme activation step was carried out at 95°C for 10 mins, followed by 14 cycles at
95°C for 15 sec followed by 60°C for 4 mins. Subsequently, the pre-amplified cDNA was
diluted 1:10 in TE buffer and was kept at -20°C until ready for use. The pre-amplification
of cDNA step was crucial to increase the sensitivity of detection for downstream
quantification using qPCR. As part of our stringent validation and confirmation
techniques, we used a series of gene targets that are specific for different retinal cell
populations, including a housekeeping gene (Hprt). The primers that were used for the
pre-amplification step are listed in the Appendix C, Table C-1.
qPCR analysis amplification efficiency test
We determined the primer efficiency and amplification efficiency by the absolute
quantification method using a Roche LightCycler® 480 Instrument and Version 1.5.0
Software (Roche, Indianapolis, IN). Pre-amplified cDNA was serially diluted to a range
of concentration (1, 1:10, 1:100, 1:1000). This comparison ensured that the preamplification process amplified genes with a wide variation of abundance. The
comparative threshold (CT) values were plotted against the log concentration qPCR
product and the slope was calculated. The closer the slope is to -3.33, the closer the
amplification efficiency is to the 100% ideal, which indicates that there is a doubling of
product per cycle. In addition, we performed linear regression analysis to show the
correlation between gene expression measurements from our samples for the primers we
validated, and a standard curve. In this study, we used CT values ranging from 15-30 in
our assays. Three biological replicates were evaluated and the CT values were normalized
to the endogenous gene (Hprt) control and compared to the CT values obtained from the
pre-amplifed cDNA from murine, non-sorted retinal cells.
qPCR reaction
For qPCR reaction we prepared a final volume of 10L PCR reaction mixture
using TaqMan® Universal Master Mix, diluted pre-amplified cDNA, primers and
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Nuclease Free water. Plates were analyzed on a Roche LightCycler® 480. Instrument
conditions included first a hold step of 50°C for 2 mins followed by 95°C for 10 mins.
Next, we performed 40 cycles of 95°C for 15 sec followed by 60° for 1 min. All
measurements were made in replicates of 4. Relative quantification was performed using
CT after determining the values of CT for the reference gene (housekeeping) and the
target genes in each sample. The relative fold change (Rq) was calculated using the
following formula: Rq= 2−ΔCT, where ΔCT = (CT target gene − CT reference gene). Data
are presented as mean ± SEM. Differences between two means were assessed with
ANOVA and Tukey’s post-hoc test (PRISM, Graph Pad, La Jolla, CA). Differences were
considered significant at p<0.05.
Immunohistochemistry
Murine retinal sections embedded in low melting point agarose were prepared
following our published methods (144). Briefly, tissue sections were blocked with 10%
goat serum and permeabilized with 2.5% Triton X-100. The following primary antibodies
were used per manufacturers conditions: anti-RNA-Binding Protein With Multiple
Splicing (RBPMS; rabbit polyclonal IgG, Santa Cruz Biotechnology, 1:100 dilution);
anti- -synuclein (SNCG, rabbit polyclonal IgG, GeneTex, 1:100 dilution); anti-BrainSpecific Homeobox/POU Domain Protein 3A (BRN3A, goat ployclonal IgG, Santa Cruz
Biotechnology, 1:10 dilution); anti-Neuronal Class III ß-Tubulin (TUJ1, mouse
monoclonal IgG2a, Covance, Princeton, NJ; 1:100 dilution); anti-HNK-1/N-CAM
(CD57, Clone VC1.1, mouse monoclonal IgM, 1:10 Dilution); and CD15 (Clone:MC480, mouse monoclonal IgM, Biolegend, 1:25 dilution). The appropriate Alexa Fluortagged secondary antibodies (Invitrogen, Waltham, MA; 1:200 dilution) and TO-PRO3
iodide (Invitrogen; 1:4000 dilution) were used to indicate the location of the antigens of
interest and nuclei, respectively. Sections were viewed and images were obtained using a
Nikon C1 (Nikon, NY) confocal microscope within the Imaging Core Facility in the
Hamilton Eye Institute. All microscope settings, including laser levels and gain, were
held constant to allow for relative comparisons of signal intensity within and between
experiments.
Immunofluorescence
Live Thy1.2+CD48negCD15negCD57neg sorted cells (50,000 cells) were washed
once with Hanks Balanced Salt Solution (HBSS) in followed by centrifugation at 1200
RPM x 5 mins at RT. Cells were labeled with SYTO®59 (100nM) for 10 mins in a HBSS
at 37°C followed by multiple washes with HBSS for 5 mins each. Cells were plated on a
glass bottom microwell dish (35mm petri dish, 14mm microwell; MatTek Corporation,
Ashland, MA) and sealed with coverslip. Analysis performed using a Nikon C1 (Nikon,
NY) confocal microscope within the Imaging Core Facility in the Hamilton Eye Institute.
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Optic nerve processing, imaging and counting
Eyes along with optic nerves were enucleated from mice immediately after
euthanasia. Optic nerves were cut close to the globe and were fixed in 0.8%
paraformaldehyde and 1.22% glutaraldehyde in 0.08 M phosphate buffer. They were
subsequently rinsed in buffer and post-fixed in 1% osmium tetroxide. After dehydration,
the specimens were embedded in Epon 812 plastic. Sections (0.8μm thick) were cut on
an ultramicrotome (Reichert-Jung Ultracut E Ultramicrotome), stained with pphenylenediamine (PPD) for 30 min. Digital images were taken using 10x and 4x
objectives using a MicroFire digital camera (Optronics®, Goleta, CA) mounted onto a
Nikon Eclipse E800 light microscope (Nikon). Multiple contiguous photomicrographs
were taken at 60x magnification to provide a continuous representation across the optic
nerve. A scale of optic nerve damage similar to that used by Clark and colleagues was
used to assign a numeric value to the appearance of the nerve (David Cantu-Crouch, IokHou Pang, Mitchell D. McCartney, Abbot F. Clark; unpublished protocol). The numeric
value is based upon the presence/absence of darkly stained axoplasm and presence of
gliotic scars.
IOP measurements
IOP was measured using the induction–impact tonometer (Tonolab tonometer,
Colonial Medical Supply, Franconia, NH) for rodents according to the manufacturer’s
recommended procedures. When measuring IOP, the tonometer was fixed in a vertical
position to a support stand by means of clamps. The mouse was gently restrained by hand
on an adjustable stand, and the eye was oriented in such a way that a distance of 1–4 mm
was maintained between from the tip the probe to the cornea of the eye. Six consecutive
IOP readings were averaged. IOP readings obtained with Tonolab have been shown to be
accurate and reproducible in various mouse strains, including DBA/2J.
Results
The Thy1+CD48neg surface phenotype is not sufficient to identify murine RGCs
Murine retinal cells express two distinct isoforms of Thy1Thy1.1 and Thy1.2
(218-220). We compared the binding of Thy1.1 and Thy1.2 to dissociated murine retinal
cells and show the majority of murine retinal cells exhibit immunoreactivity against
Thy1.2 but not Thy1.1 (Figure 4-2, Thy1.2+ at 53.9% versus Thy1.1+ at 1.7%). Current
RGC isolation techniques use selection based on Thy1-positivity and CD48-negativity by
antibody-capture (209, 210) or magnetic cell isolation (211, 213). Our data demonstrate
that a small percent of Thy1.2+ cells were also immunopositive for CD48 (11.2%) and
that inclusion of CD48 as a negative selection marker did not significantly decrease the
number of Thy1.2+ cells (Figure 4-3, left panel). To determine if the Thy1.2+CD48neg
cells were RGCs, we probed the cells for the expression of the RGC signature marker -
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Figure 4-2.
RGCs

Thy1+CD48neg surface phenotype is not sufficient to identify murine

Left panel: Pseudocolor plots were gated on live nucleated cells based on FSC and SSC
profiles. Based upon these characteristics, 84.6% of the cells were live after retinal
dissociation. Middle panel: A negligible number of live retinal cells were Thy1.1+
(1.1%), whereas 53.9% were Thy1.2+, demonstrating that in mouse Thy1.2 is the
preferred surface marker. Right panel: The majority of the Thy1.2+ cells (88%) were
CD48neg.

Figure 4-3.

Lack of specificity of current RGC isolation methods

There was no significant difference in the percent of live Thy1.2+ and Live
Thy1.2+CD48neg cells demonstrating that the addition of CD48 as a negative selection
marker is insufficient to further enrich for RGCs. Only 60% of LiveThy1.2+CD48neg are
SNCG+ indicating that many contaminating cell types remain in the LiveThy1.2+CD48neg
cell population. Gray histogram represents control and black line represents experimental
sample.
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synuclein (SNCG). Consistently, we found that a large proportion of Thy1.2+CD48neg
cells were not SNCG+. Figure 4-3 right panel, illustrates that 60% of Live
Thy1.2+CD48neg cells were positive for SNCG, suggesting that there is ~40%
contamination by non-SNCG+ cell types. To address which non-RGC cell types are
present within the Thy1.2+CD48negSNCGneg phenotype, we performed qPCR analysis on
the sorted cells. Using the absolute quantification method, we determined the optimal
concentration of pre-amplified samples that would be suitable for our validation step and
calculated the efficiency of amplification (Figure 4-4). Our qPCR method is presented in
Figure 4-4. Results shown in Figure 4-5 reveal the degree of heterogeneity of the
enriched RGCs using only Thy1.2 and CD48 as surface markers. Specifically,
Thy1.2+CD48neg cells expressed genes associated with multiple retinal cells, including
amacrine, Müller, bipolar, horizontal, photoreceptors and retinal pigment epithelial cells.
Table 4-1 lists the specific genes associated with the various cell types. Our data
demonstrates that selection based solely on Thy1 and CD48 expression is insufficient to
isolate highly enriched RGCs.
Confirmation of additional surface markers to be used as negative selectors and
intracellular RGC markers
We used IHC to determine the retinal localization patterns of other surface
markers that were expressed by contaminating cells. CD15 has been described as a
marker of retinal interneurons including amacrine and bipolar cells (221), while CD57
has been shown to label glial cells and photoreceptors (222). Our data demonstrate that
CD15 (Figure 4-6A) is localized in the interface between the inner nuclear layer (INL)
and inner plexiform layer (IPL) and in the proximal INL (arrows), where amacrine cells
are located. Occasional CD15+ cells were observed in the ganglion cell layer (GCL),
which are most likely displaced amacrine cells (arrows). CD57 immunoreactivity (Figure
4-6B) was abundant in the outer plexiform layer (OPL) and in a radial pattern through the
INL. Punctate staining was also present in the GCL, which are likely astrocytes or
displaced amacrine cells. Collectively, these results show that these surface
markersCD15 and CD57can be used as negative selectors to remove non-RGCs
from the Thy1.2+CD48neg cell population.
To verify that the commonly accepted RGC intracellular markers are specific for
RGCs (175, 208, 212, 223), we labeled murine retinal sections with antibodies against
SNCG, BRN3A [Brain-specific homeobox/POU domain protein 3A (Pouf4l)], TUJ1
[neuron-specific class III beta tubulin (Tubb3)] and RBPMS [RNA binding protein with
multiple splicing (Rbpms)]. SNCG showed abundant expression in the GCL (Figure
4-7A). Abundant BRN3A (Figures 4-7B) labeling was observed in the GCL. However,
multiple cells in the INL that border the IPL are also immunopositive for BRN3A. Based
upon their location, they are likely amacrine cells. TUJ1 (Figure 4-7C) was very
abundant in the GCL and in radial labeling patterns throughout the retina that extend up
to the ONL. Lastly, RBPMS was highly expressed by cells in the GCL (Figure 4-7D)
and a small subpopulation of cells in the INL (arrow). Collectively, these data
demonstrate that SNCG-, BRN3A-, TUJ1- and RBPMS-positive cells are present in the
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Figure 4-4.

Validation of our improved protocol for the enrichment of RGCs

(A) Schematic representation of our validation analyses of Live
Thy1.2+CD48negCD15negCD57neg sorted cells. (B) Amplification and standard curves to
evaluate primer efficiency. Left panel: amplification curves of the ten-fold dilution series
for all the primers. Right panel: Standard curves depicting CT plotted against the log of
the starting quantity of template for each dilution. The efficiency of the all PCR reactions
was between 90–100% (−3.6 ≥ slope ≥ −3.3). All samples were prepared and analyzed in
triplicate.

78

.
Figure 4-5.
analysis

Identification of Thy1.2+CD48neg cells using qualitative real time PCR

The expression levels of a panel of 25 genes expressed by various retinal cell
typesamacrine, Müller, bipolar, horizontal, photoreceptor and retinal pigment epithelial
cellsin Thy1.2+CD48neg cells were normalized to the levels present in unsorted total
retinal cells. The Thy1.2+CD48neg population showed contamination with other retinal
cell types. Target gene expression levels are presented as Log2 fold change based on the
ΔCT calculation using Hprt as a housekeeping gene and water as negative control.
MeanSEM.
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Table 4-1.
Genes used in gene expression analyses as part of the validation of our
RGC enrichment protocol
Retinal Cell Type

Genes Expressed by Retinal Cell Type

Retinal Ganglion Cell

Pou4f1; Rbpms; Sncg; Tubb3; Chrma6; Rbfox3;
Nef-H

Amacrine

Gad2; Fut4; Calb2; Pvalb; Slc6a9; Pcp4; Vip;
Thy1

Astrocytes

Aqp4; Prdx6; Gfap; Slc1a3; Pax2

Müller

ApoE; Abca8a; Vim; Aldh1a1

Bipolar

PkcaPcp4; Rcvrn; Slc1a2

Horizontal

Rcvrn; Prox1; Ntrk1; Lhx1, Lim2, Calb2

Photoreceptors (Cone and Rod)

Nrl; Rom-1; Crx; Pxph2; Arr3

Retinal Pigment Epithelial Cells

Cd68; Rpe65

Housekeeping Gene

Hprt
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Figure 4-6. Immunohistochemical localization of surface antigens used in our
RGC sorting protocol
Cellular localization of the surface proteins CD15 and CD57 in retinae from C57BL/6J
mice. Sections from C57BL/6J mouse retinae were labeled with antibodies against (A)
CD15 and (B) CD57. TO-PRO-III iodide staining labeled nuclei of all retinal cells (blue).
Abbreviations: GCL=ganglion cell layer; IPL=inner plexiform layer; INL=inner nuclear
layer; OPL=outer plexiform layer; ONL=outer nuclear layer. Scale bar: 10μm.
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Figure 4-7. Immunohistochemical localization of intracellular RGC markers used
as part of the validation process of our sorting protocol
Cellular localization of intracellular proteins SNCG, BRN3A, TUJ1 and RBPMS in
retinae from C57BL/6J mice. Sections from C57BL/6J mouse retinae were labeled with
antibodies against (C) SNCG, (D) BRN3A, (E) TUJ1, and (F) RBPMS. TO-PRO-III
iodide staining labeled nuclei of all retinal cells (blue). Abbreviations: GCL=ganglion
cell layer; IPL=inner plexiform layer; INL=inner nuclear layer; OPL=outer plexiform
layer; ONL=outer nuclear layer. Scale bar: 10μm.
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GCL and can be used to validate the identity of the cells that we isolate using our array of
cell surface markers. Even though BRN3A and RBPMS also label a small subset of
(likely) amacrine cells, we are confident that requiring all enriched RGCs to express all
four RGC markers will yield a nearly pure RGC population.
Live Thy1.2+CD48negCD15negCD57neg RGC express all signature intracellular
markers SNGC, BRN3A, TUJ1 and RBPMS
Our expanded cell sorting strategy is presented in Figure 4-8. Because
Thy1.2 CD48neg cells expressed many markers associated with retinal cells other than
RGCs, we added additional surface markersCD15 and CD57to our sorting strategy
to remove these contaminating cells. Our methodology included the negative selection of
these cell surface markers to enrich for naïve RGCs that could be used in downstream
analyses. Collectively, we were targeting the removal of monocytes, as well as glial,
amacrine and photoreceptor cells. Prior to cell surface labeling, we added purified mouse
anti-CD16/32 antibody to block FcRII/III, thus reducing false positive immunoreactivity
(224) (224, 225). Our flow cytometry-based cell sorting validation studies included
examination of pre- (Figure 4-9) and post-sorted cells (Figure 4-10) to confirm that the
post-sorted cells that were isolated using cell surface markers expressed all four RGC
intracellular markers: SNCG, BRN3A, and TUJ1, and RBPMS. Consistently, we
observed 99-100% positivity for all of the intracellular markers in the post-sorted cells,
demonstrating the isolated cells were very highly enriched, if not pure RGCs. We ensured
consistency of our results across multiple systems using two other cytometer systems, the
MACSQuant® Analyzer 10 and the FlowSight®. Our novel method was standardized as
we obtained reproducible results (Figure 4-11, Figure 4-12).
+

Using confocal microscopy, we investigated the morphological appearance of the
sorted cells. Live Thy1.2+CD48negCD15negCD57neg cells were stained with SYTO® 59
dye showing nuclear integrity. Cells showed bright blue fluorescence and strong
intracellular staining (Figure 4-13). This result confirms
LiveThy1.2+CD48negCD15negCD57neg sorted cells show the morphology associated with
RGC.
Validation of the enriched RGC population by qPCR analyses
Qualitative PCR analyses (Figure 4-14) shows that the highly enriched RGC
population had a many fold increase in the expression of all four RGC intracellular
markers: Sncg, Pouf4l, Tubb3 and Rbpms. As expected, genes found in other retinal cells
were expressed at significantly lower levels than in unsorted retinal cells. Moreover, our
improved sorting methodology removed the contaminating retinal cell types that were
present in the Thy1.2+CD48neg cells (compare Figure 4-5 and Figure 4-14). These
mRNA analyses further validated our RGC enrichment strategy.
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Figure 4-8.

Optimized FACS-based cell sorting strategy

Schematic representation of RGC isolation by flow cytometry using multiple surface
markers. Step 1: Cells were labeled with Zombie Aqua™ for live/dead cell analysis
followed by step 2: blocking of FcRII/III (mouse anti-CD16/32) to minimize nonspecific labeling. Step 3: Cell surface labeling was performed using the following
antibody cocktail: anti-mouse anti-CD90.2 Alexa Fluor 700; anti-CD48 PE-Cy7; antiCD15 PE and anti-CD57 Brilliant Violet 421 to yield
LiveThy1.2+CD48negCD15negCD57neg cells. Single labeled fluorochrome-beads were
used as controls.
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Figure 4-9.

Surface marker expression of pre-sorted retinal cells

Far left panel: Live retinal cells show two distinct populations of Thy1.2 (Thy1.2hi and
Thy1.2low) based upon expression levels per cell. Right panels: Representative FACS
plots show the expression of surface markers used for negative selectionCD48, CD15,
CD57in pre-sorted Thy1.2hi and Thy1.2low retinal cells. Labeled retinal cells were
sorted for Thy1.2hiCD48negCD15negCD57neg population. Selection for sorting included the
positive selection of Thy1.2hi (36%). This population was further selected for CD48neg
(3%), followed by CD15neg (20%) and CD57neg (36%). Grey indicates isotype controls,
colored solid lines indicates experimental samples.
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Figure 4-10. Purity of post-sorted RGCs based on the surface marker and
intracellular RGC markers
Far left panel: LiveThy1.2+CD48negCD15negCD57neg cells show expression of Thy1.2+
(95%). Top right panels present representative FACS plots show the negligible
expression of surface markers in sorted LiveThy1.2+CD48negCD15negCD57neg cells,
demonstrating the efficiency of the sort. Lower row panels show representative FACS
plots of the expression of intracellular RGC markers in
LiveThy1.2+CD48negCD15negCD57neg cells. 99-100% of all cells express SNCG, BRN3A,
TUJ1 and RBPMS, all well characterized RGC markers. This new sorting method
(Thy1.2hiCD48negCD15negCD57neg) shows improvement over the previously used
methodology (LiveThy1.2+CD48neg) using additional surface markers. Grey indicates
isotype controls, colored solid lines indicates experimental samples.
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Figure 4-11. Consistency of flow cytometry results using MACSQuant®
Dissociated murine retinal cells from C57BL/6J mice were labeled for cell surface
markers based on the sorting protocol. Sample was acquired using a MACSQuant®
Analyzer 10 from Miltenyi Biotec. Results show consistency between the two different
cytometers (BD FACS Aria and MACSQuant®).

Figure 4-12. Intracellular expression of the RGC marker RBPMS in Live
Thy1.2+CD48negCD15negCD57neg cells
Representative images from a cohort of 250,000 pictures at 20x of cells using the
FlowSight® Imager. Results show the expression of Thy1.2 surface and RBPMS
intracellular markers.
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Figure 4-13. Live Thy1.2+CD48negCD15negCD57neg show RGC morphology
(A) Representative image of sorted cells after cultured overnight at 37°C/5%CO2 in RGC
culture media showing RGC-type morphology. (B) Representative images of sorted cells,
immediately after sort.
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Figure 4-14. Validation of Live Thy1.2+CD48negCD15negCD57neg cells using qPCR
analyses
Graph depicts expression of different retinal cells markers in
Live Thy1.2+CD48negCD15negCD57neg that were normalized to the mRNA expression
measured in total primary murine retinal cells. Genes associated with RGCsSncg,
Pouf41, Tubb3 and Rbpmsshowed increased gene expression or mRNA transcripts
compared to non-RGC associated genes. Target gene expression levels are presented as
Log2 fold change based on CT calculation using Hprt as housekeeping gene. Mean ±
SEM; n=3 biological replicates were performed in triplicate.
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Highly enriched RGCs can be isolated from a mouse model with elevated IOP and
optic nerve damage
We sought to apply our improved RGC isolation methodology on a retinal
degenerative disease model. Members of our research group have analyzed a family of
over 100 BXD (68) murine strains and their parental strainsC57BL/6J and DBA/2Jat
5 different age cohorts to determine which strains had the phenotype of optic nerve
damage and elevated IOP (IOP). Both of these phenotypes are associated with retinal
degeneration in glaucoma. Our examination revealed that the BXD66 strain had both
elevated IOP and higher optic nerve damage compared to both C57BL/6J and DBA/2J
parental strains of mice (Figure 4-15). In addition, the optic nerves of old BXD66 mice
had an increase in axon damage and glial scarring compared to young C57L/6J and
BXD66 mice. Figure 4-16 depicts representative micrographs showing optic nerve
damage.
To determine if our RGC protocol was valid using retinae with damaged RGCs,
we applied our optimized and validated enrichment strategy on retinae obtained from
young and old BXD66 mice. We compared two different ages to investigate if our
enrichment protocol could be used on mice with compromised RGCs and if the efficiency
of the strategy was age dependent. We first compared the cellularity of retinal cells and
the percentage of live cells between the two ages of mice. Selecting for the phenotype
LiveThy1.2+CD48negCD15negCD57neg, enriched RGCs (Figure 4-17) were examined for
the presence of the same signature intracellular RGC markers that we used throughout
this investigation. Figure 4-18 shows the intracellular staining pattern in young and old
BXD66 mouse retinas. Similar to that found in C57BL/6J mice, the majority of the
enriched cells from BXD66 mice are immunoreactive toward the four intracellular RGC
markers (Figure 4-19). However, we observed a slight reduction in TUJ1 in BXD66
young and old mice compared to the C57BL/6J parental line, which may be indicative of
RGC damage in this model. When comparing the total number of retinal cells (obtained
from retinae of young and old C57BL/6J and BXD66 mice) with those of the phenotype
LiveThy1.2+CD48negCD15negCD57neg, we found similar patterns of changes (compares
both panels in Figure 4-20A). Within a strain, retinae from old mice had fewer live
retinal cells than young mice. In addition, retinae from BXD66 mice had a reduced
number of retinal cells compared to age-matched C57BL/6J mice (Figure 4-20B).
Moreover, old C57BL/6J mice had a lower percentage of
Thy1.2hiCD48negCD15negCD57neg retinal cells compared to young mice (0.9%±0.3 in
young mice compared to 0.5%±0.3 in old mice, p=0.041, Figure 4-20B). We consistently
found a marked reduction in the number of live retinal cells between BXD66 old (>12
months old) and young (5 weeks old) mice (Figure 4-20; live cells young versus old:
80% versus 48%). It is worth noting that the percentage of live cells isolated from young
pre-degenerative BXD66 mice is comparable to that obtained from young C57BL/6J
mice (compare to Figure 4-2). Retinae from young BXD66 mice also had a higher, but
not significantly different, percentage of Thy1.2hiCD48negCD15negCD57neg cells
compared to old BXD66 mice (0.4%±0.3 in young mice compared to 0.2%±0.2 in old
mice, p=0.177). Lastly, there was a significant reduction in the percentage of
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Figure 4-15.
Fewer RGCs are harvested from mice with documented
elevated IOP and optic nerve damage
Peak IOP and optic nerve damage distributions for C57BL/6J, DBA/2J and BXD66 mice.
BXD66 mice had significantly higher peak IOP (blue bars) and optic nerve damage (pink
bars) compared to C57BL/6J mice (**p<0.005 between B6 and BXD66 IOP values; ##
p<0.005 between B6 and BXD66 optic nerve damage grade). Mean ± SEM; n =4 per
group.

Figure 4-16. Optic nerve damage in C57BL/6J and BXD66 young/ old mice
Representative PPD-stained optic nerve cross-sections from C57BL/6J (young: 5-7
weeks old), BXD66 (young: 5 weeks old), and BXD66 (>12 months old) mice. Both
young C57BL/6J and BXD66 mice had a low degree of damage. In contrast, optic nerves
from old BXD66 mice presented with disorganized axon bundles, increased glial scarring
and multiple dead/dying axons. Scale bar=10μm.
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Figure 4-17. Characterization of enriched RGCs from young and old BXD66 mice
obtained through our improved flow sorting method
Representative histograms show comparison of surface expression of Thy1.2, CD48,
CD15 and CD57 in total retinal cells of young versus old BXD66 mice. Top panel: In
BXD66 young mice, live retinal cells have the following abundance levels: Thy1.2
(56%), CD48 (63%), CD15 (81%) and CD57 (66%). Bottom panel: In BXD66 old mice,
live retinal cells have the following abundance levels: Thy1.2 (41%), CD48 (77%), CD15
(80%) and CD57 (50%). Gray histogram indicates isotype controls; black solid lines
indicates antibody labeling.
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Figure 4-18. Localization of known intracellular RGC markers in BXD66
young/old mice
SNCG, BRN3A, TUJ1 and RBPMS in retinae from young and old BXD66 mice.
Sections from young and old BXD66 mouse retinae were labeled with antibodies against
(C) SNCG, (D) BRN3A, (E) TUJ1, and (F) RBPMS. TO-PRO-III iodide staining labeled
nuclei of all retinal cells (blue). Abbreviations: GCL=ganglion cell layer; IPL=inner
plexiform layer; INL=inner nuclear layer; OPL=outer plexiform layer; ONL=outer
nuclear layer. Scale bar: 10μm.
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Figure 4-19. Relative purity of sorted RGCs based upon surface marker selection
and intracellular RGC markers
Representative histograms show comparison of intracellular expression of RGC markers
SNCG, BRN3A, TUJ1 and RBPMS in Live Thy1.2+CD48negCD15negCD57neg cells of
young and old BXD66 mice. Top panel: In BXD66 young mice have the following
abundance levels: SNCG (100%), BRN3A (100%), TUJ1 (90%) and RBPMS (100%).
Bottom panel: In BXD66 old mice have the following abundance levels: SNCG (98%),
BRN3A (100%), TUJ1 (95%) and RBPMS (100%). Gray histogram indicates isotype
controls; black solid lines indicates antibody labeling.
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Figure 4-20. Comparison of live retinal cells based on sorting protocol
Percentage of Live Thy1.2+CD48negCD15negCD57neg cells in retinae from C57BL/6J
(young and old) and BXD66 (young and old) mice. **p<0.005; *p<0.05 compared to
young C57BL/6J mice. Mean±SEM; n=3 per group.
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compared to 0.4%±0.3 in BXD66 mice, p=0.024). Collectively, our data show that our
improved RGC enrichment protocol is also effective on retinae from old mice with no
retinal degeneration (C57BL/6J) and in mice with a phenotype of elevated IOP and RGC
damage (BXD66).
Discussion
A common element of the pathophysiology of several retinal neurodegenerations
is the loss of ganglion cells and their axons (14). Understanding of the mechanisms
underlying these processes is limited by the lack of a simple in vitro system with which to
study RGC function. This is in part is due to the scarce number of RGCs and the
heterogeneity present among the current cellular enrichment protocols. The use of
antibody-dependent plate adhesion, or immunopanning, originated more than 35 years
ago when it was used for the enrichment of immune cells. Barres and colleagues (209)
utilized the immunopanning system wherein they used Thy1 and CD48 to isolate RGCs.
They demonstrate the following three points: 1) Thy1 is not an exclusive marker of
murine or rat RGCs, as other Thy1+ retinal cells do not show the morphology and/or
electrophysiological characteristics of RGCs; 2) there is variation in the expression of
Thy1 positivity among RGCs; and 3) this assay only produced a 95% efficiency based on
Thy1 expression. This classical study allowed for the first time the use of immune
techniques in the field of neuroscience. Prior to the publishing of this methodology, RGC
isolation was based on density gradient centrifugation with varying yield degrees (226228). Although inexpensive and rapid, a major drawback of Barres’s methodology was
that it required the retrograde labeling of fast blue into both superior collicular and
brachia 48-hrs prior to retinal dissection. In 1999, Shoge and colleagues (229) developed
a protocol for the enrichment of rat RGCs based on magnetic cell separation via inclusion
of Thy1+ cells and the exclusion of macrophages. This method became popular because it
provided a fast method for enrichment of rat RGCs, although it required magnetic
columns and magnetic drivers for the separation. Unfortunately, their RGC enrichment
was only 31% indicating that many contaminating cells are present. Recently, Hong and
colleagues (210) combined the immunopanning and magnetic cell sorter techniques to
isolate murine postnatal (P1-4) RGCs. However, because the success of the method was
based solely on exclusion of glial fibrillary acidic protein and synthaxin 1, the purity of
the RGCs that were isolated is unknown.
We sought to develop an improved RGC enrichment strategy that could be used
by most investigators without the requirement for retrograde labeling that may alter the
physiology of RGCs. Our protocol also does not include immunopanning which is
lengthy. Our method is rapid and requires only five hours from the initiation of retinal
dissection to the completion of fluorescence activated cell sorting. Because of the
exquisite sensitivity of the method, FACS-based sorting is suited for purification of cells
that comprise a very small percentage within a cell suspension. Thus, the procedure is
ideal for the isolation and enrichment of RGCs, estimated to be about 0.5% of retinal
cells (148, 204). A caveat of our methodology is the requirement of expensive FACS
instrumentation, and the need for highly trained and specialized operator. However, most

96

academic and research facilities have flow cytometry core facilities, which should make
this method accessible to most investigators. FACS-based sorting has a tremendous
versatility because of the large number of selection markers that can be used in the
enrichment process. Typically, the selection is based on 2 to 15 complementary
parameters, which allow for acquisition of a reproducible and homogeneous phenotype
within a sample and between samples that can be used in follow up in vitro studies. This
methodology also allows for the immediate identification of viable cells and excludes
cells that are undergoing apoptosis or are already dead. In addition, the inclusion of an Fc
receptor blocker allows for exclusion of microglia, monocytes and macrophages, which
results in a higher degree of RGCs. Post-sorting analysis of enriched RGCs indicated cell
viability was 95%, confirming that external high pressure (60-70 psi) exerted on cells
during FACS had a negligible effect on their viability. Lastly, another advantage of this
methodology is the immediate verification of the sort purity, as it only takes as small
aliquot of the isolated product to verify the surface phenotype.
As part of our RGC enrichment strategy, we incorporated robust validation
components. For example, within our validation studies, we use immunohistochemistry
to validate two additional surface markersCD15 and CD57that improved the
efficiency of our sorting strategy. In addition, the stringency of FACS validation strategy
was confirmed using four RGC specific intracellular markersSncg, Pouf4l, Tubb3, and
Rbpms, which encode for SNCG, BRN3A, TUJ1, and RBPMS, respectivelyboth at the
protein and mRNA level. Furthermore, we identified the presence of non-RGCs using
multiple genes expressed by other retinal cell types using qPCR analyses. To our
knowledge, this is the first time, such a stringent validation process using both gene
expression (qPCR) and protein (flow cytometry and immunohistochemistry) analyses
have been performed on isolated and enriched murine RGCs.
As a further validation of the applicability of our enrichment protocol, we
evaluated the ability of our RGC enrichment strategy to isolate RGCs from a mouse
model with elevated IOP and optic nerve damage. Members of our collaborative group
use the BXD family of RI mice for gene mapping and quantitative trait locus QTL
analyses to identify specific genomic regions that modulate various glaucoma-associated
endophenotypes (59, 82, 230). The BXD RI strains are derived by inbreeding the
C57BL/6J and DBA/2J parental strains. BXD mice have been successfully used in vision
research to elucidate specific cause-effect predictions between genes and a quantitative
phenotype, such as differences in expression levels (68, 70, 82, 119). In these studies, we
selected the BXD66 strain due to its age-dependent elevation in IOP and optic nerve
damage (not published but available on www.GeneNetwork.org). Our intracellular flow
cytometry protein analysis revealed a similar percentage of cells that show positivity for
the surface marker Thy1.2, while negative selection of CD48, CD15 and CD57, and
concomitant positivity for the intracellular markersSNCG, BRN3A, TUJ1, and
RBPMSin both C57BL/6J mice and BXD66, irrespective of the age bin (5 weeks
versus 12 months). Nonetheless, the percentage of RGCs was significantly lower in the
BXD66 mice compared to the C57BL/6J mice, suggesting that RGCs, a population that is
already scarce in the mammalian retina, is less abundant in BXD66 mice. Our data also
highlight variation in the expression of TUJ1 in RGCs isolated from BXD66 mice at
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different ages, suggesting that differences in TUJ1 levels likely reflect altered physiology
of the damaged RGCs, rather than the absence of RGCs in these mice.
In summary, we demonstrate a powerful technique for the isolation and
enrichment of primary murine RGC with the phenotype Live
Thy1.2hiCD48negCD15negCD57neg, which concomitantly express the RGC signature
intracellular markers SNCG, RBPMS, TUJ1, and BRN3A. These cells can be used for
controlled in vitro studies of RGCs derived from healthy and disease models. The
streamlined and effective isolation and validation method described here will facilitate
subsequent research on the pathological and pharmacological processes with clinical
relevance to diseases involving RGCs.
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CHAPTER 5.

DISCUSSION AND CONCLUSION
Future Directions

Aim1: To identify the candidate gene that modulates IOP in mouse and test
translational validity of the mouse candidates using the cohorts of human glaucoma
patients
The main characteristic feature of glaucoma is the progressive and relatively slow
damage/death of RGCs (1). Ganglion cell death is also a feature of a number of other
optic neuropathies and retinopathies apart from glaucoma. The known acute induced
models that are currently used include, optic nerve crush, ischemia/reperfusion injury,
excitotoxic damage etcetera; are useful only in some aspects for glaucoma research (231).
The injury caused in these models is not just a specific damage to RGCs but a general
injury to the whole retina, therefore these models resembles more closely to other
diseases than glaucoma. To study such a progressive disease, the most relevant rodent
glaucoma model should include chronic elevation of IOP, to study high tension
glaucoma. Due to the difficulty in reproducing a standardized chronic elevated IOP
model thus far in the rodents, a main focus of interest should be to discover rodent strains
with spontaneously elevated IOP.
The mouse models with chronic IOP that are currently available are mostly knock
out models with single gene mutations, such Mendalian mutations do not correlate with
human glaucoma (231). In the past decade and a half dramatic advances has been seen in
the field of glaucoma research due the introduction of chronic inherited disease in inbred
mice strains. DBA/2J inbred line is the most well characterized mouse model of
glaucoma (64). Although this model has been extensively studied, few limitations makes
this model not ideal for studying glaucoma. In these animals, the glaucoma progression is
not due elevated IOP. The disease progression is in fact due to the secondary systemic
pigment dispersion syndrome with the associated mutations in the Gpnmb and Tyrp1 loci.
The natural history of disease in DBA/2J mice varies, depending on individual colonies
and other environmental factors. Also, even though these are inbred mice with a fixed
genetic background, they still exhibit a high degree of variability and asymmetry in
developing the disease. Only about 70% of the animals develop glaucoma since both of
these genes show incomplete penetrance (66, 67).
Because BXD mice are genetically stable inbred lines, this makes them an
informative tool for understanding human disease. The combined BXD strain set is the
largest existing mouse RI mapping panel. Using a systems genetics approach, we and
other researchers have successfully used BXD RI murine panel for studying genetic
modulators and identifying non-synonymous polymorphisms for complex polygenetic
diseases such as glaucoma, pigment dispersion syndrome, hypertension, and metabolic
disorders system (69-71). RI strains are especially useful for mapping complex traits,
since they create an immortalized mapping population that allows us to phenotype as
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many animals per genome as desired over extended periods of time which leads to more
precise phenotypic estimates invaluable to mapping complex disease traits as glaucoma.
Using this information, we can identify specific wild type BXD strains (i.e., no Tyrp1 and
Gpnmb mutations) that have elevated IOP, high optic nerve damage and iris defects that
can be used as high tension glaucoma model. We can also distinguish the strains based on
IOP and optic nerve damage grades to identify normal tension glaucoma models. Such
mouse models would be ideal to study glaucoma progression, since these mice will not
have any influence of Tyrp1 and Gpnmb genes, and natural variations due to
recombination events would ideally represent human disease states such as POAG.
Genetic studies using BXD mice are proving to be a powerful means to study
disease causing genes and pathologic mechanisms that cause disease or alter disease
susceptibility. The systems genetics approach has been widely used to identify the
genetic basis for pharmacogenetic traits and becomes increasingly more powerful with
the recent advances in genomic technologies. We can easily study a genetic association
with drug response if there is a plausible link between the gene and the drug response.
We can characterize physiological or pharmacologic effects of the genes (or genetic
variations) on disease or drug response. In spite of increased spending on pharmaceutical
research and development, the number of ‛new’ drug approvals for glaucoma has
remained relatively constant. The essential first step in the drug discovery pipeline is the
identification and early validation of disease-modifying targets. In recent years ‛systems’
approach has become popular to identify new targets to understand the cellular
mechanisms underlying a particular disease. The systems approach is geared towards
target-discovery through the study of disease in whole organisms such as mice or rats
(232). Here, we used ‛systems genetics’ to identify IOP-associated genes. In future we
can validate these as functional targets, and utilize such approach in bridging the gap
between data generation and effective drug target identification. In this study, the
identification of a novel candidateCACNA2D1linked to elevated IOP was an
exemplar to pave the way for improved drug development tailored to individuals with
glaucoma leading to personalized medicine. The outcomes of these investigations will
identify a novel therapeutic for IOP reduction that specifically targets a gene product that
was identified in bidirectional POAG studies. They will also determine if the genotype
influences response to therapy. Such results are expected to fundamentally advance the
field of glaucoma therapy, which will have positive translational impact.
Our Aim 1 studies are innovative for at least the following five reasons:
1. We have utilized a large number of aging BXD strains that are segregating for
glaucoma susceptibly genes. The DBA/2J strain has been used as the standard
model for pigmentary dispersion glaucoma by a substantial number of
investigators. We have greatly enriched this field by introducing new variant
strains that have both Tyrp1 and Gpnmb mutations and new strains with wild type
genotypes that have a highly variable disease state. Our set of 66 aging BXD
strains is sufficiently large to allow us to identify loci, and even genes, that cause
glaucoma.
2. We used the complete sequence data for DBA/2J and the dense genotypes for all
BXD strains. We now have a database of ~4M SNPs, 400K indels, and thousands
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of inversions and CNVs that are segregating among the BXD strains. The
consequence of this is that our QTL analysis and the massive genomic/genetic
data led to more efficient extraction of functional sequence variants linked to IOP.
3. We used a novel systems genetics approach to help define molecular networks
that modulate IOP. By using the eye transcriptome data and aging BXD IOP
phenotype data, we were able to assemble gene-phenotype networks. This is one
of the most exciting aspects and is a departure from the typical experimental
paradigm of testing and comparing knockout and wildtype mouse models of
human disease. This project represents a novel application of the use of
expression genetics in dissecting the transcriptome predictors of IOP and other
phenotypes associated with glaucoma.
4. We have combined mouse data sets with data from human GWA studies in a
bidirectional manner to identify a candidate gene most likely to modulate IOP.
5. We provide the scientific community with a novel gene
candidateCACNA2D1that influences IOP based upon a systems genetics
approach by using BXD strains.
Aim 2: To identify and validate regulator of Sncg in primary mouse RGCs
Glaucoma is characterized by ON axon loss and RGC degeneration and is often
linked with elevated IOP. In a complex disease such as glaucoma, the molecular
processes driving the complex disease usually affects genes acting in concert. One of the
strategies that we used for these studies was systemslevel approaches to investigate
transcriptional networks and pathways within pathologically relevant cellsRGCs. Our
integrated analysis of transcriptional networks associated with Sncg susceptibility data
and phenotypic information allowed us to identify specific pathways to be connected to
disease states, and thereby can identify disease pathways and their genetic regulators as
new targets for therapeutic intervention. We took the full advantage of the BXD RI
strains in combination with a powerful combination of systems biology, microarray
analysis, expression genetics, bioinformatics along with conventional techniques to study
mechanism of gene regulation.
Although the molecular mechanisms responsible for RGC death is not well
known, considerable evidence suggests the involvement of synuclein as a component
of RGC death. Recent evidence shows that mitochondrial dysfunction is present in some
glaucoma patients. POAG patients have been reported to have increased levels of
mtDNA mutations as well as deficiencies in complex-I driven ATP synthesis and
respiration (233). Although evidence of mitochondrial dysfunction was reported in
patients with glaucoma, there is no direct evidence that mitochondrial dysfunction
contributes to the pathogenesis of glaucoma. In our study the interaction of synuclein
with mitochondria raises the intriguing possibility that these two components of RGC
damage might have a synergistic inter-relationship that contributes towards the
complexities of glaucoma. Possible mechanisms of such an interrelationship include
synuclein directly or indirectly impairing mitochondrial function, mitochondrial
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dysfunction exacerbating synuclein levels, or, perhaps, synuclein levels and
mitochondrial dysfunction enhancing each other in a self-amplifying cycle, or,
synuclein influencing mitochondrial fission-fusion reaction. Intriguingly the ER is well
connected, both physically and functionally, to the mitochondria allowing the signaling
and exchange of metabolites between these two organelles. Since both synuclein and
prefoldin-2 act as chaperone proteins, their levels may block ER to Golgi membrane
trafficking. These two chaperone molecules may also perturb microtubule transport
which may lead to impairment of both the appropriate delivery and distribution of
mitochondria within RGCs and their axons, particularly from the critical area of the
synaptic terminals, as well as the disposal of potentially reactive oxygen species
producing dysfunctional mitochondria. In future such studies will enhance our
understanding of the pathophysiological mechanisms of mitochondrial dysfunction in
glaucomatous neurodegeneration, and offer the scientific basis for identifying and
developing new therapeutic strategies that could protect not only RGCs and their axons,
but also the central visual pathway against glaucomatous damage.
Our Aim 2 studies are innovative for the following reasons:
1. Here, we combined cutting edge methodologies of systems genetics, bidirectional
studies using multiple species, meta-analyses, immunohistochemistry, FACS
sorting and gene knockdown studies to identify and validate the identity of a
genetic modulator of Sncg, a gene that has been previously implicated in RGC
death in glaucoma.
2. We exploited partial correlation analysis to solidify the relationship between Sncg
and Pfdn2 in the mouse retina. The statistically significant partial correlation
between Sncg and Pfdn2 reflects gene–gene interactions, as well as a regulatory
relationship between the genes.
3. We exploited the transcriptome data from both healthy and diseased eyes to
evaluate the relationship between Sncg and the candidate gene. In healthy retinas,
the protein levels of both genes are significantly correlated in a positive manner.
In contrast, the relationship between the genes appears to have changed to an
inverse relationship with reduced Sncg levels in glaucoma as the disease
progressed.
4. Pfdn2 is located in the Qrr1 on chromosome 1, which is a genomic region of
unusually high gene density and contains major regulatory QTLs for various
behavioral, metabolic, physiologic and immunological processes including
diverse epileptic traits(188, 234). This region also controls the expression of a
remarkably large number of genes, including genes that are associated with some
of the classical traits that map to distal Chr 1 (e.g., seizure susceptibility).
5. Knocking down Pfdn2 expression in enriched primary murine RGCs significantly
reduced the expression of Sncg, confirming that Pfdn2 regulates Sncg expression
in murine RGCs. The knock down studies were performed in vitro and the cells
remained alive for 48 hours post-transfection.
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6. The findings presented in this study provide strong support for the value of
systems genetics, especially GeneNetwork, in discovering new upstream
regulators of genes that can be confirmed by molecular analysis.
Aim 3: To isolate and validate primary murine RGCs from healthy and
recombinant inbred mouse model of elevated IOP
Glaucoma is a complex, multifactorial, neurodegenerative disease that causes
irreversible vision loss. A universal element in the pathophysiology of the many
etiologies of glaucoma is the death of RGCs and the degeneration of their axons (1).
Identifying the genetic basis or cellular mechanisms causing RGC degeneration would be
the first step toward the development of efficacious therapies to slow or reverse RGC
damage, in turn preserving vision. But scarce number of RGCs that can be isolated from
a retina provides a major challenge to develop therapies.
A great deal has been learned about the cell and molecular biology of glaucoma
through research on cultured RGCs. However, there are significant limitations with
current RGC cultures. RGCs are terminally differentiated, and therefore, primary RGCs
must be prepared from rodent eyes for each experiment conducted. A number of
laboratories have emphasized the need for having a verified and validated RGC cell line
to determine the mechanism of RGC cell death or to evaluate therapy efficacies (202,
203, 235). In attempt to address this need, in 2001, a rat retinal cell line (RGC-5)
displaying certain characteristics of RGC (expression of the specific cell-type markers
including Thy1, Brn-3C, neuritin, NMDA receptor, GABA receptor, and
synaptophysin) was derived by transforming postnatal day 1 rat retinal cells with Ψ2EA1
virus (236). Multiple questions have been raised regarding the nature and/or identity of
these cells. A 2009 study demonstrated that the RGC-5 cell line contained mouse, rather
than rat, biomarkers (203). As recent as 2013, it was (235)demonstrated that RGC-5 cells
were 661W cells, a mouse SV-40 T antigen-transformed photoreceptor cell line, rather
than rat RGCs. There have been more than 230 publications that have used the RGC-5
line to test various glaucoma-related hypotheses (237). Unfortunately, the outcomes of
those investigations are very likely null and void. The lack of an authenticated RGC line
represents a large unmet need for the vision research community at large. The
heterogeneity of the cells in retina contributes to lack of reproducibility to isolate
homogeneous RGCs. Therefore, to investigate RGCs cellular mechanisms, it is critical to
develop such methodology. Commercially available kits for RGC isolation are exclusive
for rats and for mice the protocols are based on magnetic separation and immunopanning.
Both approaches require lengthy isolations and their yields vary. FACS is a powerful
technique for analysis of cells in suspension allowing separation of cells based on
parameters such as size and granularity, providing a quantitative and qualitative analysis
with high sensitivity. The purification system using flow cytometry has not been
standardized for the isolation of and standardization of primary murine RGCs from
dissociated retinae. We can use this powerful technologyFACSas the first step of
generating a stable, immortalized, homogeneous murine RGC population from murine
retinae.
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Classically, IHC analyses of cross sections of ganglion cell layer flat mounts are
used for the detection of surface and intracellular markers associated with RGC (207,
208, 238, 239). Despite its extensive use there are a series of limitations such as fading
and photobleaching of fluorescence, limited sensitivity and the presence of false-negative
or false-positive results. The tissue structure may or may not allow appropriate exposure
for the immune binding of proteins. Rather than the use of IHC for protein detection
exclusively, the use of flow cytometry as a complement technique will provide a major
sensitivity and a faster and more objective way to acquire and record data.
Enhancing RGC viability (neuroprotection) or RGC function (neuroenhancement)
remains a major goal of basic and translational research. In future, such cell lines or
isolate cells can be used to define the molecular biology of the process of ganglion cell
death, by manipulating such biochemical events that occur in a dying ganglion cell to
increase the chance of cell survival. Elucidation of cell death and neuro-protective
pathways would lead to generation of novel therapeutic targets to prevent glaucoma
progression. Other possibilities include, molecular profiling to identify and characterize
the RGC subtypes which are the first targets of the disease—the cells most susceptible to
the disease—and help devise new prevention and therapy. RGC-based screening
technologies can be developed to enabled drug discovery scientists to develop models of
interconnected cellular pathways, extract important information for specific disease
models, and build companion diagnostic programs around relevant cellular biomarkers
for therapeutics. The benefits from this work will pave the way for studying mechanisms
of RGC neuroprotection and death in glaucoma and in future targeted neuroprotective
strategies can be developed to treat glaucoma.
Our Aim 3 studies are innovative for the following reasons:
1. We provide the first standardized method for the enrichment of adult murine
primary RGC by FACS.
2. LiveThy1+CD48neg phenotype is not the phenotype of a homogenous/pure RGC
population. The stringency of the additional positive markers: Thy1.2 and
negative cell surface: CD15, CD57, CD48 selection markers increased the
homogeneity of the resultant RGC population.
3. Our two step validation strategy included the use of qPCR and flow cytometry.
The innovation is based on (1) pre-amplification od cDNA; (2) the combination of
amplicons; (3) intracellular protein examination by flow cytometry. Our cutting
edge gene transcriptional assays based on characterized the homogeneous
population of the isolated cells and our flow cytometry strategy affirmed the
purity of the isolated cells.
4. Our sorting method enriches for a homogeneous population of RGCs.
5. We provide the scientific community with a novel and fully validated
methodology to isolate murine RGCs that can be used to dissect molecular
mechanisms of cell damage/death in glaucoma as well as evaluate potential
treatments for glaucoma.
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Glaucomics—Future of Glaucoma Research
Visual disorders like glaucoma massively impact health, both in developed and
developing countries. Visual disorders represent one of the largest health care
expenditures in the United States, costing approximately $139 billion per year (240). A
complex disease such as glaucoma is best conceptualized as a syndrome displaying a
presumably common clinical end-point, but with heterogeneous molecular underpinnings
and host–environment interactions. Despite advances in our understanding of the
pathophysiology of glaucoma, the diagnostic criteria and associated endophenotypes are
still evolving. Ophthalmology in the 21st century needs a fresh new look at the ways in
which novel diagnostics are developed so as to catalyze true innovations for personalized
healthcare. This thesis is an introduction of omics science and systems diagnostics to
ophthalmology, a field that can benefit enormously from personalized medicine, and
which has sadly lagged behind in systems diagnostics compared to fields such as
oncology. Glaucomics offers tremendous opportunities to integrate glaucoma research
and clinical practice with omics science, systems diagnostics, and personalized visual
health. Glaucomics can be defined as “The integrated use of multi-omics and systems
science approaches towards rational discovery, development, and tandem applications of
diagnostics and therapeutics, for glaucoma specifically, and for personalized visual
health” (241). Access to high-throughput technologies has enabled scientists and
clinicians to examine genomes, transcriptomes, proteomes, metabolomes, and other
omics information. By combining mouse and human omics data we can identify novel
biomarkers and systems diagnostics for glaucoma. By isolating different retinal cell types
contributing to glaucoma we can perform high throughput drug screening and high
content data analysis to better understand cellular function (Figure 5-1). My dissertation
is a step towards development of “Glaucomics” as a bridge between high throughput
technology and visual health. Philosophers defined the eye as a window to the soul long
before. Now as scientists we need address this cliché to determine its scientific basis and
clinical relevance.
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Figure 5-1. Glaucomics
The integrated use of multi-omics and systems science approaches towards rational
discovery, development, and tandem applications of diagnostics and therapeutics, for
glaucoma specifically, and for personalized visual health.
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APPENDIX A. SUPPLEMENTAL DATA FOR CHAPTER 2
Table A-1.

IOP values of BXD strains at 9.1-13 months age
BXD
Strains
B6D2F1
C57BL/6J
DBA/2J
BXD1
BXD2
BXD5
BXD6
BXD8
BXD9
BXD11
BXD12
BXD13
BXD14
BXD15
BXD16
BXD18
BXD19
BXD20
BXD24
BXD27
BXD29
BXD31
BXD32
BXD33
BXD34
BXD36
BXD38
BXD39
BXD40
BXD42
BXD43
BXD45
BXD48
BXD50

Average Average
Female
Male
Overall
IOP
IOP
IOP
18.25
17.00
17.63
15.00
15.42
15.23
16.77
17.00
16.84
18.20
X
18.20
11.33
X
11.33
12.17
14.17
13.17
12.50
X
12.50
17.00
17.00
17.00
11.75
16.75
14.25
14.83
14.60
14.75
13.25
15.50
14.38
13.50
13.25
13.38
18.75
20.00
19.38
15.67
17.00
16.33
15.88
18.50
16.75
19.25
17.00
18.13
13.08
15.25
14.17
10.67
11.33
11.00
18.00
16.00
17.00
19.64
16.60
18.38
13.50
15.83
14.67
14.33
X
12.63
13.33
14.75
13.90
19.00
17.00
18.00
18.57
19.63
18.95
14.88
14.75
14.83
9.25
10.25
9.58
11.50
14.50
13.21
14.50
12.25
13.75
9.50
12.88
11.75
17.63
18.13
17.88
17.25
15.00
16.50
9.25
9.33
11.90
12.33
12.75
12.50
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SE
0.38
0.78
0.70
1.08
0.83
1.98
X
2.11
1.61
0.94
1.48
0.38
0.43
0.54
0.87
0.83
0.86
1.08
1.00
1.13
1.11
1.73
0.70
0.56
0.79
0.46
0.93
1.14
0.64
0.88
0.47
1.52
0.95
2.13

Table A-1.

(continued)
Average
BXD
Average
Male
Strains Female IOP
IOP
Overall IOP
BXD51
18.50
17.40
17.89
BXD55
14.50
15.17
15.00
BXD56
18.31
20.00
18.88
BXD60
14.38
14.50
14.45
BXD61
17.68
19.80
18.24
BXD62
12.10
17.75
14.61
BXD63
X
17.33
17.33
BXD65
13.88
14.33
13.45
BXD66
15.33
20.88
18.50
BXD67
16.50
18.50
17.50
BXD68
18.63
13.25
16.83
BXD69
16.77
18.50
17.04
BXD70
17.63
14.13
16.46
BXD71
11.50
13.83
12.50
BXD73
15.83
18.29
17.94
BXD75
15.50
14.20
14.85
BXD77
18.00
17.50
17.64
BXD83
13.50
16.75
16.21
BXD84
14.50
12.63
13.75
BXD85
16.43
15.71
16.07
BXD86
16.67
X
16.67
BXD87
18.50
15.30
16.50
BXD89
14.15
16.50
14.54
BXD90
15.83
14.50
15.30
BXD92
14.17
13.83
14.00
BXD95
18.13
17.38
17.75
BXD98
18.80
18.50
18.69
BXD99
18.50
18.00
18.25
BXD100
16.33
17.50
16.55
BXD101
13.25
X
13.25
BXD102
14.67
16.50
15.28
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SE
1.50
0.60
1.20
0.59
1.66
1.93
0.60
0.88
1.47
0.71
1.90
0.55
0.96
2.07
0.90
0.67
1.46
0.75
0.74
1.14
1.28
0.89
0.65
1.57
1.62
1.39
0.72
0.32
0.65
0.83
1.12

Table A-2.

Cacna2d1 expression in BXD strains whole eye
BXD
Cacna2d1
SE
Strains
Expression
B6D2F1
9.049
0.04
D2B6F1
8.874
0.114
C57BL/6J
9.498
0.071
DBA/2J
7.543
0.148
BXD1
7.927
0.355
BXD2
7.813
0.338
BXD5
7.646
0.102
BXD6
7.759
0.058
BXD8
8.883
0.15
BXD9
7.502
0.602
BXD11
7.314
0.42
BXD12
7.833
0.117
BXD13
8.847
0.4
BXD14
8.897
0.625
BXD15
8.827
0.397
BXD16
7.517
0.017
BXD18
9.241
0.353
BXD19
7.749
0.352
BXD20
7.674
0.241
BXD21
8.793
0.02
BXD22
9.086
0.378
BXD23
8.852
0.558
BXD24
9.148
0.118
BXD25
8.884
0.227
BXD27
7.531
0.13
BXD28
8.819
0.008
BXD29
7.478
x
BXD31
7.685
0.384
BXD32
8.097
0.449
BXD33
8.472
0.743
BXD34
9.105
0.405
BXD36
7.85
0.184
BXD38
7.408
0.275
BXD39
9.111
0.653
BXD40
7.836
0.313
BXD42
7.668
0.259
BXD43
7.69
0.334
BXD44
9.096
0.376
BXD45
7.705
0.102
BXD48
7.516
0.488
BXD48a (BXD96)
9.708
0.328
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Table A-2.

(continued)
BXD Strain

Cacna2d1
Expression
BXD50
9.399
BXD51
8.319
BXD55
9.159
BXD56
9.31
BXD60
7.585
BXD61
9.035
BXD62
7.754
BXD63
7.885
BXD64
7.812
BXD65
9.086
BXD65a (BXD97)
8.771
BXD65b (BXD92)
7.708
BXD66
8.727
BXD67
9.088
BXD68
8.456
BXD69
7.846
BXD70
7.552
BXD71
6.91
BXD73
9.506
BXD73a (BXD80)
9.221
BXD75
7.627
BXD77
8.902
BXD83
9.541
BXD84
7.828
BXD85
7.634
BXD86
8.718
BXD87
9.207
BXD89
7.535
BXD90
8.091
BXD98
7.854
BXD99
8.864
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SE
0.11
0.429
0.439
0.067
0.158
0.14
0.048
0.127
0.026
0.029
0.207
0.129
0.359
0.248
0.634
x
0.3
0.239
0.058
0.14
0.312
0.446
0.081
0.031
0.457
0.912
0.078
0.624
0.297
0.59
0.24

APPENDIX B. SUPPLEMENTAL DATA FOR CHAPTER 3
Table B-1.

Sncg expression in retina of BXD strains
BXD Strain

Sncg
Expression
B6D2F1
14.175
D2B6F1
13.958
C57BL/6J
13.747
DBA/2J
14.267
BXD1
13.772
BXD2
13.995
BXD5
14.15
BXD6
13.513
BXD8
13.669
BXD9
13.716
BXD11
14.413
BXD12
13.761
BXD13
12.68
BXD14
13.71
BXD15
12.652
BXD16
13.205
BXD18
12.84
BXD19
13.68
BXD20
13.744
BXD21
13.488
BXD22
14.169
BXD24a
14.274
BXD27
13.907
BXD28
13.681
BXD29
13.781
BXD31
13.065
BXD33
13.133
BXD34
13.585
BXD36
13.753
BXD38
13.379
BXD39
14.385
BXD40
13.284
BXD42
13.837
BXD43
13.761
BXD44
14.406
BXD45
13.782
BXD48
14.378
BXD48a (BXD96) 14.363
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SE
0.106
0.235
0.147
0.095
0.071
0.188
0.127
0.359
0.252
0.066
0.085
0.087
0.15
0.135
0.035
0.315
0.124
0.3
0.107
0.211
0.09
0.139
0.117
0.131
0.191
0.147
0.058
0.161
0.126
0.139
0.191
0.159
0.128
0.267
0.17
0.105
0.08
0.08

Table B-1.

(continued)
BXD Strain

Sncg
Expression
BXD50
14.031
BXD51
13.875
BXD53
13.847
BXD55
13.799
BXD56
13.076
BXD60
13.698
BXD61
14.469
BXD62
13.859
BXD63
13.717
BXD65
13.832
BXD65a (BXD97)
14.066
BXD65b (BXD92) 13.901
BXD66
13.473
BXD67
14.07
BXD68
13.716
BXD69
13.685
BXD71
14.327
BXD73
13.283
BXD73a (BXD80)
13.616
BXD73b (BXD103) 13.552
BXD74
13.843
BXD75
13.957
BXD77
14.361
BXD81
14.184
BXD84
14.197
BXD85
13.768
BXD86
13.915
BXD87
13.557
BXD90
13.706
BXD95
13.7
BXD98
14.315
BXD99
14.356
BXD100
13.78
BXD101
14.012
BXD102
14.074
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SE
0.176
0.151
0.089
0.293
0.192
0.208
0.157
0.204
0.173
0.046
0.211
x
0.244
0.227
0.199
0.205
0.472
0.264
0.165
0.14
0.192
0.278
0.147
0.277
0.217
0.187
0.226
0.098
0.127
0.244
0.148
0.111
0.324
0.152
0.227

Table B-2.

Pfdn2 expression in BXD strains retina
BXD Strain

Pfdn2
Expression
B6D2F1
13.707
D2B6F1
13.696
C57BL/6J
13.628
DBA/2J
13.843
BXD1
13.674
BXD2
13.682
BXD5
13.265
BXD6
13.555
BXD8
13.206
BXD9
13.405
BXD11
13.906
BXD12
13.561
BXD13
12.492
BXD14
13.719
BXD15
12.786
BXD16
13.714
BXD18
12.492
BXD19
13.267
BXD20
14.136
BXD21
13.767
BXD22
13.309
BXD24a
13.952
BXD27
14.017
BXD28
13.353
BXD29
13.626
BXD31
13.001
BXD33
13.535
BXD34
13.238
BXD36
13.87
BXD38
13.465
BXD39
14.415
BXD40
13.064
BXD42
13.65
BXD43
13.57
BXD44
14.028
BXD45
13.774
BXD48
13.53
BXD48a (BXD96) 13.553
BXD50
13.625
BXD51
14.319
BXD53
13.45
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SE
0.23
0.263
0.215
0.235
0.137
0.25
0.309
0.141
0.285
0.081
0.088
0.109
0.104
0.199
0.135
0.408
0.085
0.15
0.108
0.219
0.267
0.277
0.199
0.223
0.135
0.094
0.339
0.298
0.229
0.199
0.196
0.205
0.322
0.497
0.411
0.186
0.108
0.134
0.225
0.193
0.216

Table B-2.

(continued)
BXD Strain

Pfdn2
Expression
BXD55
13.366
BXD56
13.302
BXD60
13.047
BXD61
14.066
BXD62
13.371
BXD63
13.555
BXD65
13.473
BXD65a (BXD97)
13.891
BXD65b (BXD92)
13.377
BXD66
13.38
BXD67
13.701
BXD68
13.408
BXD69
13.586
BXD71
13.792
BXD73
13.085
BXD73a (BXD80)
13.974
BXD73b (BXD103) 13.268
BXD74
13.052
BXD75
13.484
BXD77
13.966
BXD81
13.179
BXD84
13.239
BXD85
13.546
BXD86
13.821
BXD87
13.627
BXD90
13.458
BXD95
13.546
BXD98
13.413
BXD99
13.897
BXD100
13.416
BXD101
13.703
BXD102
13.382
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SE
0.265
0.194
0.305
0.246
0.314
0.187
0.254
0.177
x
0.402
0.208
0.172
0.358
0.477
0.314
0.209
0.1
0.041
0.224
0.165
0.226
0.122
0.245
0.222
0.211
0.353
0.21
0.196
0.293
0.199
0.192
0.238

Table B-3.

Gene ontology of Cytochrome-c oxidase activity

Database: molecular function Name: Cytochrome-c oxidase activity ID:GO:0004129
C=16; O=2; E=0.12; R=17.06; rawP=0.0060; adjP=0.0590
Index
User ID
Gene
Gene Names
Entrez
Ensembl
Symbol
Gene
1
ILMN_2657141 Surf1
Surfeit gene 1
20930 ENSMUSG00000015790
2

ILMN_1254971 Cox6b1

Table B-4.

Cytochrome c oxidase, subunit VIb polypeptide 110323 ENSMUSG00000036751

Gene ontology for NADH dehydrogenase activity

Database: molecular function Name: NADH dehydrogenase activity ID:GO:0003954
C=18; O=2; E=0.13; R=15.17; rawP=0.0075; adjP=0.0590
Index
User ID
Gene
Gene Names
Entrez
Ensembl
Symbol
Gene
1
ILMN_1220362 Ndufa12 NADH dehydrogenase (ubiquinone) 1 alpha
66414 ENSMUSG00000020022
subcomplex, 12
2

ILMN_2985053 Ndufv2

NADH dehydrogenase (ubiquinone)
flavoprotein 2

131

72900

ENSMUSG00000024099

Table B-5.

Gene ontology for oxidoreductase activity

Database: molecular function Name: oxidoreductase activity ID:GO:0016491
C=663; O=11; E=4.86; R=2.26; rawP=0.0095; adjP=0.0590
Index
User ID
Gene
Gene Names
Entrez
Ensembl
Symbol
Gene
1
ILMN_2752552 Sod1
Superoxide dismutase 1, soluble
20655 ENSMUSG00000022982
2

ILMN_2610531 Spr

3

20751

ENSMUSG00000033735

ILMN_1220362 Ndufa12 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 12

66414

ENSMUSG00000020022

4

ILMN_2657141 Surf1

Surfeit gene 1

20930

ENSMUSG00000015790

5

ILMN_1258815 Jmjd1c

Jumonji domain containing 1C

108829 ENSMUSG00000037876

6

ILMN_2985053 Ndufv2

NADH dehydrogenase (ubiquinone) flavoprotein 2

72900

ENSMUSG00000024099

7

ILMN_2512849 Uqcrh

Ubiquinol-cytochrome c reductase hinge protein

66576

ENSMUSG00000063882

8

ILMN_1220100 Ywhae

Tyrosine 3-monooxygenase/
Tryptophan 5-monooxygenase activation protein,
epsilon polypeptide

22627

ENSMUSG00000020849

9

ILMN_2594149 Sdhc

Succinate dehydrogenase complex, subunit C,
integral membrane
protein

66052

ENSMUSG00000058076

10

ILMN_1254971

Cytochrome c oxidase, subunit VIb polypeptide 1

110323 ENSMUSG00000036751

Cox6b1

Sepiapterin reductase
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Table B-6.

Gene ontology for hydrogen ion transmembrane transporter activity

Database: molecular function Name: hydrogen ion transmembrane transporter activity ID:GO:0015078
C=71; O=4; E=0.52; R=7.69; rawP=0.0018; adjP=0.0590
Index
User ID
Gene
Gene Names
Entrez
Ensembl
Symbol
Gene
1
ILMN_2657141 Surf1
Surfeit gene 1
20930 ENSMUSG00000015790
2

ILMN_1254971 Cox6b1 Cytochrome c oxidase, subunit VIb polypeptide 1

110323 ENSMUSG00000036751

3

ILMN_1249783 Atp5c1

ATP synthase, H+ transporting, mitochondrial F1
complex, gamma polypeptide 1

11949

ENSMUSG00000025781

4

ILMN_2512849 Uqcrh

Ubiquinol-cytochrome c reductase hinge protein

66576

ENSMUSG00000063882
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Table B-7.

Gene ontology for structural constituent of ribosome
Database: molecular function Name: structural constituent of ribosome ID:GO:0003735
C=81; O=4; E=0.59; R=6.74; rawP=0.0030; adjP=0.0590
Index
User ID
Gene
Gene Names
Entrez
Ensembl
Symbol
Gene
1
ILMN_1229110 Mrpl33 Mitochondrial ribosomal 66845 ENSMUSG00000029142
protein L33
2

ILMN_2646163 Rpl7

Ribosomal protein L7

19989

ENSMUSG00000043716

3

ILMN_2883147 Mrpl12

Mitochondrial ribosomal
protein L12

56282

ENSMUSG00000039640

4

ILMN_1236904 Mrpl23

Mitochondrial ribosomal
protein L23

19935

ENSMUSG00000037772
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APPENDIX C. SUPPLEMENTAL DATA FOR CHAPTER 4
Table C-1.
List of primers used for gene expression analysis as a component of
the validation of RGC enrichment protocol
Gene symbol Taqman® Gene Expression assays
(Primers)
Abca8a
Aldh1al
Aqp4
Calb2
Cd68
Gad2
Hprt
Lhx1
Lim2
Nrl
Ntrk1
Pcp4
Pov4f1
Prdx6
Prkca
Prox1
Pvalb
Rbpms
Rom1
Rpe65
Slc1a3
Slc6a9
Sncg
Tubb3
Vim

Mm00462440_m1
Mm00657317_m1
Mm00802131_m1
Mm00801461_m1
Mm03047340_m1
Mm00484623_m1
Mm01545399_m1
Mm01297482_m1
Mm00624623_m1
Mm00476550_m1
Mm01219406_m1
Mm00500973_m1
Mm02343791_m1
Mm00725435_s1
Mm00440858_m1
Mm00435969_m1
Mm00443100_m1
Mm02343791_m1
Mm00436364_g1
Mm00504133_m1
Mm00600697_m1
Mm00433662_m1
Mm00488345_m1
Mm00727586_s1
Mm01333430_m1
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